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Cell tracking is important because the information it provides is required to 
inform cell based treatment development. Additionally, it has a diagnostic purpose for 
detecting infection/inflammation diseases with labelled cells, a technique that has 
become part of routine clinical practice. Currently only gamma emitting radiotracers 
for single photon emission computed tomography (SPECT) are available to label cells 
for routine service. PET (positron emission tomography) exhibits better resolution than 
SPECT and its use in cell tracking would improve image quality, detectability and 
quantification for smaller lesions.  
The studies presented in this thesis report on development of cell labelling 
techniques with positron emitting radionuclides. The production and characterisation 
of complexes of copper-64 with dithiocarbamate (DTC) analogues and 
bis(thiosemicarbazones) (BTSCs) are described. Their labelling efficacies and 





Cu-GTSM were observed, a high percentage of the radiotracer leakage from the 
labelled cells was still problematic. Efflux kinetics were similar for all the complexes 
used suggesting that the efflux mechanism was the same in all cases. In an alternative 
approach, a novel lipophilic complex of the long lived PET isotope, zirconium-89, was 
synthesised and characterised. [89Zr]-Zr(oxinate)4 showed good retention in the 
labelled cells 24 hr after labelling as well as moderate uptake in many types of cells 
including human leucocytes and mouse multiple myeloma (MM) cells (eGFP-5T33).  
In vivo imaging and ex vivo tissues counting was used to compare cell tracking with 
[89Zr]-Zr(oxinate)4 and [
111
In]-In(oxinate)3 labelled MM cells. The main organs of the 
homing radiolabelled cells were similar in MM model. However, mice injected [
111
In]-
In(oxinate)3 labelled cells showed higher accumulation of activity in the kidneys than 
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those of [89Zr]-Zr(oxinate)4 that might indicate the greater release and metabolism of 
the 
111
In radiotracer released from the labelled cells. The localisation of [89Zr]-
Zr(oxinate)4 in labelled MM cells was confirmed by sorting of homing organ (liver, 
spleen, bone marrow) homogenates based on green fluorescence protein (GFP) 
expression up to 7 days post inoculation, which showed that radioactivity remained 
predominantly in GFP-positive cells confirming that radionuclide loss from the 
labelled cells was minimal and that the cells remained alive at 7 days post injection. In 
addition we demonstrated that mice inoculated [89Zr]-Zr(oxinate)4 labelled cells can be 
tracked by PET imaging for 14 days after inoculation. 
It was concluded that while Cu-64 radiolabelling of cells was ineffective 
because the majority of radioactivity was lost from cells by 24 hr, the novel complex 
[89Zr]-Zr(oxinate)4 can be successfully synthesised with acceptable quality and very 
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Chapter 1: Introduction 
Nowadays, cell labelling plays an important role in many imaging applications 
such as in infection and inflammation diseases (1) as well as the study of cell functions 
for better understanding and improving diagnostic and treatment of diseases (2). 
Extension of the advance knowledge of molecular biology in the medical field leads to 
the era of cell-based therapies such as stem cell therapy (3) and cancer immunotherapy 
(4). The cell labelling approach would therefore provide more important information 
about the in vivo fate, biodistribution and survival of cells in these applications. 
Properties of ligands and tracers chosen for labelling and tracking the labelled cells 
should be related to the applications. For instance, tracers for tracking stem cells 
requires a longer period of following than tracking of labelled cells for investigation of 
infection or inflammation foci.  Then, the detectability period and stability of tracers 
after labelling the cells become the important criterion for finding suitable ligands or 
approaches.    
For the last few decades, tracking of radiolabelled cells has been clinically 
approved as a routine service in nuclear medicine since the pioneering work on 
autologous blood cell labelling was launched in the 1970s (1, 5). Images of 
radiolabelled isolated white blood cells have been routinely used to detect 
infection/inflammation foci in a range of diseases. The basic principle for labelling is 
non-specific labelling using lipophilic and metastable complexes of 
111
In (with oxine 
(6, 7), tropolone (8, 9) and occasionally other bidentate chelators (6, 10-12), and later 
technetium-99m,(2, 13, 14) for gamma camera imaging. Tracers used in studies of cell 




1.1 Single photon emission computed tomography (SPECT) imaging 
In gamma scintigraphy and SPECT imaging, radiotracers that emit gamma 
photons are injected into the body. The emitted photon in the body produces images 
based on cellular function and physiology rather than morphological information. 
Combination of SPECT (or PET, as described later) with the other modalities, such as 
Computed Tomography (CT), generates more detailed anatomical information. This 
combination of modalities has been accepted to produce the highest sensitivity among 
other techniques and is widely used in clinical practice. The spatial resolution in 
nuclear scintigraphy is limited.  Since the spatial resolution of commercial micro 
SPECT and PET scanners are recently improved (15, 16), these techniques are 
becoming more valuable to investigate a wide range of diseases in animal models 
including monitoring cell tracking (16). It is presupposed that this labelling approach 
does not cause significant impairment of the biological function of labelled cells (17) 
and that alteration to cells‟ proliferation and function can be minimised by careful 
control of radiation dose (18). Although the biological effects of radiolabelling on cells 
needs much more investigation to fully understand the information provided by 
radionuclide cell tracking, SPECT isotopes have been widely employed to study cell 
trafficking, and planar imaging with gamma emitters has been used for more than thirty 
years for imaging the migration of white blood cells to detect infection and 
inflammation in the clinic. Cells can be labelled by direct labelling technique with 





as described below. 
1.1.1 Indium-111 (
111
In), a gamma emitting isotope, emits photons around 171 





complexes have been investigated for labelling cells. The following 
111
In complexes 
have been used either in clinical practice or research. 
1.1.1.1 
111
In-oxine (oxyquinoline) (structure of 8-hydroxyquinoline (oxine) 
shown in Figure 1.1) was approved as a clinical radiopharmaceutical used for imaging 
inflammation and infection (5) in routine Nuclear Medicine services and became a gold 
standard for intraabdominal infection detection (19). 
                                        
 Figure 1.1: Structure of 8-hydroxyquinoline (oxine) 
 
111
In-oxine which has neutral and lipophilic properties directly labels white 
blood cells by passive diffusion into the cells. The lipophilic complex is then 
dissociated and then 
111
In strongly binds to intracellular macromolecules. The 
radionuclides remaining within the cells allow the gamma camera to detect labelled  
cells (20).  However, 
111
In prefers to form complex with transferrin in plasma with 
greater stability than oxine resulting in reduced efficiency to label leukocytes (21) in 
plasma. Therefore in the 
111
In-oxine labelling procedure it is necessary to remove 
plasma before the labelling processes.  Moreover, 
111
In-oxine labels not only 
leukocytes but also erythrocytes in the same manner. Thus, for in ex vivo labelling of 
leukocytes with this tracer it is necessary to remove red blood cells and plasma before 
the labelling process. Disadvantages of this technique are that it requires well trained 
personnel and is time consuming (22). Because this isotope binds to intracellular 
macromolecules, free 
111
In remains trapped in the reticuloendothelial system when 
labelled granulocytes undergo apoptosis or necrosis after finishing their functions (23).  
24 
 
The method has been used to investigate various applications of cells such as cell-based 
therapies. Techniques to label progenitor cells, stem cells, dendritic cells (DC) and 
tumour-infiltrating lymphocytes (TILs) with 
111
In-oxine have been investigated (24, 
25). However from in vitro studies, this tracer was shown to be released from the 
labelled hematopoietic progenitor cells (HPCs) to the extent of more than 30 % and 60 
% after 24 and 48 hours, respectively (26). Comparison of in vivo biodistribution in rats 
with and without myocardial infarction 1 hr after injection of 
111
In-oxine labelled 
HPCs, showed high uptake in lung which cleared by 24 hr in both groups. After 96 hr 
different uptake between infarcted and non-infarcted animals was visualised suggesting 
migration and function of 
111
In-oxine labelled HPCs to the infarcted area.                                        
 1.1.1.2 
111
In-tropolone (tropolone structure shown in Figure 1.2) is another 
radioindium complex used to label cells. 
111
In-tropolone can label cells in
 
the presence 
of plasma (27).  
                                                             
      Figure 1.2: Structure of tropolone 
This property offers benefit to label specific cell types such as platelets which 
need to be maintained under physiological conditions during the labelling procedure to 
decrease adverse effect on the radiolabelled cells. Reports from researchers using 
111
In-
tropolone (9, 27) suggest that the labelling efficiency to label blood components is 
comparable with that of 
111
In-oxine.  




complexes for assessment 
as radiotracers for labelling cells in plasma rather than in saline or buffer to overcome 
the limitations of the 
111
In-oxine labelling procedure. In 1985, Thakur and colleagues 
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In-Merc) to label leukocytes 
and platelets in presence of plasma (11, 28). The labelling efficiencies of 
111
In-Merc 




In-tropolone complexes. The success of platelet labelling was illustrated by 
minimisation of platelet aggregations and the high percentage of labelled platelets that 
could be recovered from dogs. Another advantage of this 
111
In complex was that it 
enabled efficient labelling of blood components with either one or two steps using 
111
In-Merc solution or in the form of lyophilised kit of Merc, respectively (11). In 1999, 
Ellis et al. reported studies of the heterocyclic bidentate ligands, 6-alkoxymethyl-3-
hydroxy-4H-pyranones (3-hydroxy-6-propoxymethyl-4H-pyran-4-one and 6-
butoxymethyl-3-hydroxy-4H-pyran-4-one), chelated with 
111
In to assess cell uptake 
with leukocytes, erythrocytes, platelets (12). The function of the labelled cells was 
compared to those labelled with 
111
In-tropolone, including the effect of plasma 
concentrations (12). Radiolabelling yields of both 
111
In pyranone complexes with red 
blood cells was decreased by increasing of plasma concentrations. Efficient 
radiolabelling, however, was achieved when plasma concentration between 10% and 
20% was presented. Although the cell labelling efficiency and intracellular stability of 
the radiolabel in the cells among 
111
In complexes were similar, the perturbation of 
metalloenzymes was observed more in the 
111
In-tropolone labelled cells than in the 
111
In-3-hydroxy-6-propoxymethyl-4H-pyran-4-one labelled cells. Those results 
suggested the potential of 
111
In pyranones complexes as radiotracers to label cells 
especially in the presence of a small amount of plasma.  
1.1.2 Technetium-99m (
99m
Tc) is the gamma emitting radionuclide most 
commonly used in diagnostic nuclear medicine due to generator availability and 





which are either routinely used in the clinical practice or have been investigated for 
labelling of cells.   
1.1.2.1 
99m
Tc hexamethylpropylene amine oxime (exametazime) (
99m
Tc-
HMPAO (Figure 1.3)), a neutral and lipophilic complex, has been used for imaging 
leukocytes since the 1980s in the same period as 
111
In-oxine (29).  
 
        





Tc-HMPAO labelling procedure is similar to the 
111
In-oxine labelling 
technique but it can be performed in plasma. The 
99m
Tc-HMPAO becomes changed to a 
hydrophilic form after passing the cell membrane and moving to intact organelles. 
99m
Tc-HMPAO showed preferential labelling of granulocytes over mononuclear cells 
(lymphocytes), and labelling yield was decreased when increasing the proportion of 




Tc-HMPAO does not bind to macromolecules 
in the cells, so higher amount of free 
99m
Tc might be washed out. In vitro study showed 
17 % dissociation of 
99m
Tc-HMPAO from cell within one hour after cell labelling and 
an increased rate of efflux was found in biological conditions (23). Because of normal 
biodistribution of 
99m
Tc-HMPAO-leukocytes in liver, spleen, bone marrow, kidneys 
and gastrointestinal tract, suboptimal detection of lesions in those areas occurs. 
However, labelling leukocytes with technetium-99m is cheaper and more available than 
indium-111. Moreover, its photon emission is more suitable for gamma camera to 
produce better resolution (31) with lower radiation exposure. This might be 










showed lower labelling efficiency (about 2-fold) and shorter retention time than 
111
In-
oxine (32).  Migration of dendritic cells (DC) labelled with 
99m
Tc-HMPAO in vivo was 
evaluated. The result indicated that 
99m
Tc-HMPAO was not promising to study DC 
tracking because of low labelling efficiency and low stability in this cell type (33).  
1.1.2.2 
99m
Tc tin fluoride colloid (
99m
Tc–SnF2 colloid) has been used to label 
white blood cells for scintigraphy of infection and inflammation in routine nuclear 
medicine especially in Australia (34). From in vitro studies, 
99m
Tc–SnF2 colloid 
preferentialy labelled erythrocytes (approximately 75%) over neutrophils (14%) and 
lymphocytes (12%) in whole blood. Additionally, most of radiotracer (75%) binds 
internally to neutrophils by phagocytosis mechanism whereas reversible and lower 
affinity binding to cells surface of other cell types was observed (35).  Since 
biodistribution of whole blood containing 
99m
Tc–SnF2 colloid labelled leukocytes 
showed high accumulation in liver and spleen, those organs
 
might take up the 
99m
Tc–
SnF2 colloid released from the red cells in vivo (36). Limited detectability of lesions 
within or adjacent to those areas is a pitfall of this technique. Also the range of cell 
types that can be labelled is limited: it is only useful for phagocytic cells. However, 
technetium tin fluoride colloid is beneficial for imaging lesions in bowel (37). 
1.1.2.3 
99m
Tc complexes with dithiocarbamates have been used to label cells. 
Dithiocarbamate (Figure 1.4) derivatives are known as chelators for variety of metals 
and are able to form lipophilic complex with radionuclides (38).  
 
                                Figure 1.4: Structure of dithiocarbamates                
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TcN(DDC)2) to label white blood cells in crude leukocytes, with preferential 
labelling of granulocytes (39). In addition, after incubation with cell free plasma up to 4 
hours, 77 % of tracer remained in the cells while no differences in cell viability 
between labelled cells and control were observed. Bis(N-ethoxy-N-
ethyldithiocarbamate)nitride technetium-99m (
99m
TcN(NOET)2) (a lipophilic complex 
developed for myocardial perfusion imaging)  showed high efficiency (more than 80%) 
to labelled pure granulocytes with no cytotoxicity. The localisation results from 
microautoradiography indicated that this tracer labelled nuclei rather than cytoplasm 
(40). A similar result was shown in 
188
Re-N(NOET)2 (40). Another study showed that 
increasing lipophilicity of dithiocarbamate derivatives (CH3(CH2)n-2CS2MgBr) by 
changing their aliphatic linear side chains leads to increased labelling efficiency with 
the whole blood as well as specific to label leukocytes (n =10 gave the highest labelling 
yield around 62%) (41). 
1.2 Magnetic resonance imaging (MRI) 
There have been large numbers of reports of methods for magnetic labelling of 
cells for tracking by magnetic resonance imaging (42, 43). In MRI a magnetic field is 
used to manipulate hydrogen nuclei (proton) in water in the tissues or organs to 
produce contrast. Differences in biochemical structures or proton density in tissues 
generate contrast in images which can be detected with MR imaging. MRI is 
commonly used in clinical practice because it is a non-invasive technique and generates 
high spatial resolution images that simultaneously give both physiological and 
anatomical information (44). Moreover, it is widely utilised for imaging labelled cells 
both in preclinical (45) and clinical studies (46). Basically, cells need to be labelled 
with magnetic resonance (MR) contrast agents such as gadolinium (Gd) based 
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compounds, superparamagnetic iron oxide particles (SPIO) or ultrasmall 
superparamagnetic iron oxide particles (USPIO).  
1.2.1 Gadolinium (Gd) complexes have been widely used in clinical practice to 
detect tumours (47)
 
and for labelling cells for experimental studies (48). Terreno et 
al.(49) demonstrated two approaches to incorporate Gd-based contrast agent (Gd-
HPDO3A) into rat hepatocarcinoma cells. Electroporation and simple incubation 
showed differences in subcellular localisation of Gd, with Gd in the cytoplasm when 
delivered by electroporation but in endosomes when labelled by via simple incubation 
(49). However, the passive labelling required high concentration of Gd chelates and 
long incubation time (50). Electroporation techniques might stress labelled cells and 
cause a significant decrease in their viability and survival. In addition, the ability of 
cells to differentiate might be inhibited (51). Therefore, this method may be not 
suitable for clinical practice.  A Gd chelate, Gadolinium-fullerenol, was developed and 
showed improvement of signal intensity in mesenchymal stem cells (MSC) however 
cell proliferation was diminished (52).  
1.2.2 Superparamagnetic iron oxide nanoparticles (SPIO) consist of an iron 
oxide (magnetite) core and a hydrophilic coating (53). They have high relaxivities. 
There are many methods to prepare SPIOs resulting in variations in properties such as 
core size, shape and outer coating (e.g. dextran-coated). Those differences affect the 
ability to label cells (54), pharmacokinetics, biodistribution and intracellular uptake 
(55). Cells take up dextran-coated SPIOs via endocytosis mechanisms (e.g. 
phagocytosis, pinocytosis). Labelling studies were performed in non-phagocytic cells 
such as lymphocytes (56, 57)
 
and in phagocytic cells such as neutrophils, macrophages 
and monocytes (58, 59) by incubating SPIOs with the cells. In addition, mesenchymal 
stem cells can be labelled with SPIO. Although this labelling technique has little or no 
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effected on cell properties, high concentration of labelled cells and long incubation 
times are required (60). Therefore, transfection reagents (61) or mechanical approaches 
such as electroporation (62) have been utilised to introduce contrast agents into the 
cells to improve labelling efficacy. In order to increase specificity to targeted cells, 
modifications of dextran coated SPIOs by covalently conjugating with polyclonal 
immunoglobulin G (63) or monoclonal antibody fragment (64) were developed.                               
 Recently, there have been developments of magnetic resonance reporter genes 
for indirect labelling cells. Transduced cells expressing the iron storage protein ferritin 
can be visualised in MRI (65, 66). In addition, genes encoding the synthesis of iron 
oxide nanoparticles (like synthetic SPIO) from magnetotactic bacteria were used to 
transfect cells which could then be detected with MRI (67).  
Ultrasmall superparamagnetic iron oxide particles (USPIO) around 10-40 nm in 
size, have strong relaxivity. USPIO were taken up by phagocytosis in macrophages in 
the reticuloendothelial system in the same manner as SPIO. There has been research to 
demonstrate accumulation of USPIO taken up cells in lymph nodes (68). The labelling 
efficiency of USPIO with non-phagocytic cells can be improved by attaching 
monoclonal antibodies to USPIO, resulting in increased labelling efficiency through 
receptor-mediated endocytosis (69). However, this technique could alter long term 
biological functions of cells so further investigation will be required.  
 Although MRI modality seems to be a promising technique to study cell 
migration, various limitations still remain. Sensitivity of this imaging technique is 
required to improve because currently MRI cannot detect low target density with small 
amounts of labelled cells. Signal in the labelled cells can be diluted along with cell 
division and the contrast agents can be transferred to neighbouring cells or tissues 
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especially following death of the labelled cells. Moreover, this modality is limited for 
implantable device patients. 
1.3 Optical imaging (OI) 
 Optical imaging is another approach which has been widely used to label cells 
for tracking especially in preclinical research. For optical imaging, contrast agents used 
to label the cells generate visible light for detection by the specific devices. Two types 
of contrast are characterised according to how they produce the light: bioluminescence 
and fluorescence.    
1.3.1 Bioluminescence used to label cells produces light from chemical reaction 
of substrates catalysed by enzymes converting chemical energy to light (3) which is 
detected by a charged coupled device (CCD) (70). This technique usually needs a 
genetic engineering approach to introduce a bioluminescence gene such as luciferase 
(luc gene) into target cells before transferring into the host (71). Consequently, 
transfected cells encode an enzyme to react with administered specific substrate (e.g. 
luciferin) to emit photons. In general, luminescence background level is very low in 
most animals resulting in rather high signal to noise ratio (72). However, the problems 
for this technique are the limited detection of signals in deep tissues (73) (because of 
light attenuation and scatter by tissues) and that the encoded enzymes and high 
administered amount of substrates have high potential to induce human 
immunogenicity (74). Therefore, this approach is limited to small animals for 
preclinical purposes. 
1.3.2 Fluorescent imaging (FLI), fluorescent dyes or proteins which are 
incorporated into the cells are excited by external light to higher energy states before 
emitting longer wavelength photons (75). In the case of fluorescent proteins (such as 
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green fluorescent protein (GFP)), fluorescent genes are introduced to target cells 
genetically in the same manner as bioluminescence strategy. The expressed fluorescent 
proteins are excited and the emitted photons are detected.  Alternatively, fluorescent 
dyes or probes are directly labelled to the cells. In case of dyes (e.g. DiD and DiO) 
which have lipophilic properties, they can intercalate in cell membrane of the targeted 
cells (76). However, the fluorescent signals can be decreased through cell proliferation 
and signals from labelled dead cells may be taken up by host phagocytic cells (77). 
Excitation light non-specifically activates endogenous molecules (e.g. collagen) in the 
tissues resulting in high background of autofluorescence (78).  In addition, the 
limitation on imaging in deep tissues due to attenuation of both incident and emitted 
light is still a problem. Development of near infrared (NIR) fluorophores has helped 
solve these problem and detectable depth is enhanced to around 7-14 centimetres (79). 
Nonetheless, quantitative imaging from these depths is still difficult to address in 
clinical contexts.  
Quantum dots (QD) are inorganic fluorophores that contain colloidal 
semiconductor cores usually coated with chemicals. The special properties of QD are 
that their emission is in the near infrared region, which reduces autofluorescence, and 
their photonic stability and brightness allows long observation in tissues, e.g. for over a 
week (80).  The investigation of their potential toxicities still requires further research.  
In the endogenous labelling techniques for both BLI and FLI, the targeted cells 
essentially require genetic engineering to express bioluminescent or fluorescent 
proteins.  In case of exogenous label, probes or dyes can diffuse into cells or adhere to 




1.4 Positron emission tomography (PET) imaging 
 Since the advent of radionuclide cell tracking in the 1980‟s, advances in other 
areas of biomedicine have created new applications for in vivo cell tracking in humans. 
Understanding of the distinct role of different leukocyte types, and the development of 
methods for separating and isolating them, has led to new possibilities to exploit 
imaging to track individual immune cell types (81) (e.g. eosinophils (2, 82), 
neutrophils(2, 13, 82), T-lymphocytes (4) and dendritic cells (83) in cancer, 
atherosclerosis, stroke, transplant medicine, asthma and allergy. Developments in 
regenerative medicine and cell based therapies have created roles for tracking in cell-
based therapies such as stem cells and chimeric antigen receptor-expressing T-
lymphocytes (84, 85). Conventional  cell labelling methods have been applied in some 
of these areas preclinically and in humans (2) but for clinical use some of these new 
applications will require detection of small lesions and small numbers of cells beyond 
the sensitivity of gamma camera imaging with 
111
In (e.g. coronary artery disease, 
neurovascular inflammation and thrombus). This has led to widespread interest in 
developing positron-emitting radiolabels for cells to exploit the enhanced sensitivity, 
quantification and resolution of clinical PET compared to clinical scintigraphy and 
SPECT. Therefore positron-emitting radiotracers have been sought to label cells and 
are described below. 
1.4.1 Fluorine-18 (
18
F) is a short half life PET isotope (110 min). It is most 






F-FDG is a 
glucose analogue which can be taken up and incorporated into glucose metabolising 
cells (mostly in tumour cells) in a similar way to glucose. Since 
18
F-FDG cannot be 
metabolised by enzymes after hexokinase in the glycolytic pathway, it  is trapped after 





FDG inside the cells which can be detected by PET scanners (86). 
18
F-FDG has been 
applied in diagnosis of many types of malignant cells including the staging of tumours. 
However, 
18
F-FDG is not specific for tumour cells. Several studies indicated that 
infected and inflammatory cells also take up this tracer (87).  Rudd et al. (87) reported 
that 
18
F-FDG was accumulated in carotid plaques 3 hr after injection of radiotracer. 
Since 
18
F-FDG showed the possibility to detect inflammatory cells in vivo, 
several attempts to label autologous leukocytes with this tracer have been made but 
glucose in the incubation medium was found to influence the labelling efficiency and 
stability (88). In the labelling protocol from Forstrom et al., the highest labelling 
efficiency was approximately 78% when heparin was used as anticoagulant and 
18
F-
FDG was directly incubated with leukocyte pellets at 37
o
C for 20 min (89).  Viability 
of labelled cells was not affected after incubation with the tracer for 60 min. Loss of 
radiolabel was slightly increased from 13% at 1 hr to 26% at 4 hr of incubation. 
However, labelling efficiency of 
18
F-FDG to leukocytes was not consistent (90-92)
 
and 
lower than that of 
111
In-oxine (90, 92). Prince and colleagues reported that the efflux 
rate of 
18
F-FDG from labelled dendritic cells post labelling was more than 20% per 
hour (93). 
18
F-FDG was used to label and image autologous human bone marrow cells 
in acute myocardial infarction (94). The labelled 
18
F-FDG bone marrow cells (BMCs) 
and CD34 positive cells showed 92 to 96 % cell viability. Infarcted myocardium was 
also detected after intracoronary infusion by this tracer (94). Thus, this technique can 
possibly be applied to follow homing and distribution of BMCs in acute myocardial 
infarction treatment.  
  With the same number of lymphocytes, 
18
F-FDG labelling of autologous T 
lymphocytes showed the same labelling efficiency as 
111
In-oxine (around 64% and 
68%) and was better than 
99m







In-oxine not only decreased T lymphocyte cytotoxic 
properties towards targeted cells (measured using the standard 
51
Cr released assay) but 
also decreased cell proliferation (32). Circulating progenitor cells (CPC) from human 
and pig were labelled with 
18
F-FDG to study tracking of CPC in acute myocardial 
infarction (MI) (95). The maximum labelling efficiency was around 90 % after 
incubation at 37
o
C for 30 min. However, tracer was significantly dissociated from the 
cells to the extent of approximately 23% to 28% within 2 hr. The labelled cells in pig 
MI models were successfully delivered to myocardium infarction (95) and imaged with 
PET/CT. The attempt to use glucose transport inhibitor, phloretin (which previously 
showed efficiency to inhibit release of glucose in red blood cells), was only efficient to 
inhibit wash out of 
18
F-FDG in vitro but not in vivo with C17.2 neural stem cells 
(C17.2 NSCs) in a tumour inflammation model (96).   
Labelling efficiency and labelling stability are major disadvantages of 
18
F-FDG 
labelled cells as well as short physical half life of 
18
F (110 min) that is a significant 
limitation to following cells migration. 
1.4.2 Gallium-68 (
68
Ga) is a short lived positron emitting isotope (half life 68 




Ga generator or a cyclotron and now 
commercial generators are widely available. Since 1977, a lipophilic complex of 
gallium-68, 
68
Ga-oxine, was reported for labelling erythrocytes and platelets (97). High 
labelling efficiency in RBCs was observed whereas inconsistent labelling yield with 
platelets was obtained. However, in vivo imaging of 
68
Ga-oxine labelled red blood 
cells and platelets in dogs was successful, detecting the high blood pool organs (heart, 




Other lipophilic complexes of 
68
Ga such as those with tropolone and 2-
mercaptopyridine-N-oxide (MPO) were investigated for the potential to label platelets 







Ga-MPO (98). The results showed that labelling yield of 
68
Ga-MPO was most reproducible and labelling yield was dependent on the amount of 
the platelets. 
68
Ga-MPO labelled platelets were used to image aorta injury in rabbit. 
The results of both PET imaging and tissue biodistribution of damaged aorta in rabbits 
injected with 
68
Ga-MPO labelled platelets showed great accumulation of the activity in 
the lesions comparing to normal controls. 
68
Ga-MPO labelled platelets showed good 
viability and in vivo labelling stability but were suboptimal to detect pulmonary 
embolus lesions in the patients (99) because 
68
Ga-MPO labelled platelets remained in 
the blood circulation for hours after injection leading to low target to background ratio 
in the early period of study and later imaging was restricted dramatically by rapid 
decay of 
68
Ga-MPO labelled platelets over the delay study.   
Although 
68
Ga complexes can be used to label cells, the major limitation is its 
short half life (68 min) that is not suitable for sequential studies.   
1.4.3 Copper radioisotopes have been used for labelling cells. Copper (Cu) has 










Cu. Most are 














are useful for therapeutic purposes. Copper isotopes have been reported to be 
promising for labelling peptides (100) and cells (92, 101-104). Among these copper 
isotopes, 
64
Cu showed striking characteristics for studying cell migration. Physical 
decay modes of 
64
Cu consist of electron capture (41%), positron (19%) which is 
suitable for PET imaging, and beta (40%) particles (105). In addition, its intermediate 
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half life, 12.7 hr, is appropriate for optimising labelling procedure as well as interval 
imaging for cell migration study over days. Cell labelling with copper-64 can be 
achieved using lipophilic tracers, such as complexes of bis(thiosemicarbazone) ligands 
(PTSM (106)), tropolonate (92) and PEG conjugates (104). 
Bis-thiosemicarbazones (BTSCs) (such as diacetyl-bis(N
4
-
methylthiosemicarbazone) (ATSM) and pyruvaldehyde bis(N
4
-
methylthiosemicarbazone) (PTSM)) (Figure 1.5) form neutral lipophilic complexes 
with copper(II).  
 
                                                       
            Figure 1.5: Structure of bis(thiosemicarbazones (BTSCs) ligands complex with 
copper (107)                    
They have been utilised as bifunctional chelators (BFCs) (108) but the labelling 
yields were not consistent. In addition, high nonspecific binding to proteins and poor 
stabilities of these complexes were reported. Although complexes of bis-
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thiosemicarbazones are not promising for BFC purposes, complex instability is an 
advantage for cell uptake. 
64
Cu-ATSM has been investigated and available as a tracer 
for detecting hypoxic cells or tissues (109, 110) and has also been evaluated in vitro 
and in vivo as a therapeutic radiopharmaceutical (111).
 
By imaging hypoxia it can 
potentially predict cancer patients‟ survival rate (112) in response to radiotherapy. 
However, the potential to label cells with 
64
Cu-ATSM is limited owing to its redox 
potential allowed tracer efficient trapping only by cells in hypoxic conditions.   
Another bis-thiosemicarbazone derivative, PTSM, forms a complex with copper 
that has less selectivity for hypoxia. PTSM is a lipophilic carrier molecule for carrying 
radiocopper to passively diffuse across cell membranes according to concentration 
gradients and its lipophilic property. The mechanism of Cu-PTSM labelling of cells has 
never been clearly proved. However, it is hypothesised that this copper complex  passes 
into cells and becomes reduced to Cu(I) which is released from the complexes before 
copper trapping by intracellular molecules (101, 105) (Figure 1.6). Therefore, several 
studies have utilised Cu PTSM for labelling cells.  
 
 
              Figure 1.6: Diagram of Cu-PTSM uptake and retention by cell (101) 
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glioma (C6) cells was compared (101). The labelling efficiency of 
64
Cu-PTSM was 
moderately high, around 70%-80%, (in the presence of 5% FBS) after incubation for 5 
hr with 5 Ci of 64Cu-PTSM.  The tracer influx into cells increased with incubation 
period. However, both tracers showed rapid efflux from labelled cells, to the extent of 
more than 15% and 35% of 
64
Cu-PTSM and 15% and 45% of 
18
F-FDG by 0.5 and 2 hr 
after labelling, respectively. Only approximately 22% of 
64
Cu-PTSM was retained 
within the cells after incubation for 24 hr. Trypan blue and MTT assays indicated no 
alteration of cell viability and proliferation. In vivo imaging with C6 cells labelled with 
64
Cu-PTSM in mouse models demonstrated that lungs were the initial distribution 
organs followed by migration into liver. In contrast, the free tracer was taken up 
directly in liver, which is known to be the main metabolising organ for copper. Thus, 
for the early time point (up to around 3 hr post injection) it was assumed that detectable 





from the cells. Although the in vivo imaging could be performed up to 2 days after 
injection (around 18 hr) due to relatively long half life of 
64
Cu, tracking of 
radiolabelled cells over this period required the assumption that detected radioactivity 
in the liver is due to radiocopper labelled C6 cells or free 
64
Cu-PTSM, which could not 
be proved, because the accumulation activity in the liver of mice injected 
64
Cu-PTSM 
labelled C6 cells and 
64
Cu-PTSM alone were in the same range. 
64
Cu-PTSM-labelled 
lymphocytes have also been imaged in mouse models. The results showed firstly 
uptake in the lungs before homing to the spleen. Altogether, 
64
Cu-PTSM showed 
potential to be a tracer for study cell tracking either in vitro or in vivo in the short term. 
The leakage issue, however, requires further attention and improvement before tracking 
over several hours or days could be relied upon. 
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Imaging of rhesus monkey mesenchymal stem cells (rhMSCs) and CD34 
positive cells labelled with 
64
Cu-PTSM was performed by Huang and co-workers 
(102).  From the results of 
64
Cu-PTSM radiolabelling cells, rhMSCs showed higher 
retention of radiocopper than CD34
+ 
cells. These phenomena possibly relate to either 
size (rhMSCs are bigger than CD34
+
) or reduction potential differences between those 
cells. Studies of dose dependent effects of 
64
Cu-PTSM labelled rhMSCs cells at the 
concentration of 40 Ci/ml showed that growth rate and some differentiation properties 
of rhMSCs (such as osteogenic, chondrogenic differentiation) were altered with 
increasing of 
64
Cu-PTSM concentration. However, an optimum concentration of 
64
Cu-
PTSM was found at which it was able to label cells without any adverse effects and 
different responses to radiation depended on cell types. This leads to the conclusion 
that 
64
Cu-PTSM can be used for cell migration studies but optimised doses have to be 
verified for each cell type. 
For a recent study reported by Griessinger et al., 
64
Cu-PTSM was used to label 
mouse Th1 cells (mouse ovalbumin (OVA) T-cells receptor transgenic interferon 
(IFN)--producing CD4+T (Th1) cells). Tracking the homing of 64Cu-PTSM labelled 
Th1 cells in OVA immunised and non-immunised mice challenged with OVA to 
induce airway hypersensitivity to OVA were evaluated (106). Although the in vivo 
imaging results showed that OVA-Th1 cells labelled with 
64
Cu-PTSM could be tracked 
to the lymph node (pulmonary lymph nodes) in immunised mice challenged with OVA 
for up to 48 hr after injection labelled cells, the retention of the radiotracer in the 
labelled cells was less than 50% by 5 hr after labelling, and only 14% remained in the 
cells after 24 hr.  
Copper complexes with different BTSC derivatives were compared to exploit 
selectivity of copper complexes in hypoxic cells (107, 109). The experiments compared 
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the uptake of the tracers in either mouse mammary tumour cells or Chinese hamster 





exhibited non-hypoxia-targeted uptake by the cells (i.e. efficient uptake both at low 
oxygen concentration and at normal oxygen concentration). Copper complexes of 
PTSM and PTS on the other hand showed marginally higher uptake in hypoxic cells 
than in normoxic cells, while several complexes of ligands related to ATSM showed 
high selectivity for hypoxia. Based on these structure-activity relationships, copper 
complexes of GTS and GTSM might be proposed to be the most suitable tracers for 
labelling cells because they are extremely efficiently taken up in cells independently of 
hypoxia.   
Tropolone (water-soluble metal chelator used for 
111
In-labelling as discussed 





F-FDG in the study of Bhargava et al. (92). The results 
showed significant instability of 
64
Cu-tropolone association with the labelled cells. The 
labelling efficiency was in the same range as 
111
In-oxine and greater than that of 
18
F-
FDG. However, the efflux of 
64
Cu from the labelled cells was significant even in the 
first few hours after labelling and higher than 75% was eluted from the cells by 24 hr. 
The authors improved retention of 
64
Cu-tropolone in the labelled cells by co-incubating 
a second chelator, a membrane-permeable divalent calcium chelator (quin-MF/AM [2-
(2-amino-4-methyl-5-fluorophenozy) methyl-8-aminoquinoline-N, N, N’, N’-tetra-
acetic acid]), with 
64
Cu-tropolone and the cells. After quin-MF/AM passes through the 
membrane, intracellular esterases enzymes convert the quin-MF/AM to a negatively 
charged (hydrolysed) form with high affinity for Cu
2+
 leading to rapid binding between 
the chelator and the free copper released from 
64
Cu-tropolone (Cu-quin/MF) resulting 
in stable 
64
Cu complex remaining trapped inside the cells. With this procedure, the 
retention of the radioactivity at 24 hr post labelling of 
64
Cu labelled white blood cells 
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was significantly increased to around 80%, which can be compared with 
111
In-WBC at 
the same time point. In comparison to viability of cells radiolabelled with the other 
radionuclides, 
64
Cu-WBC showed highest viability 24 hr post labelling. The 
improvement of 
64
Cu-tropolone retention in the cells was an innovative and promising 
approach, however, the modified procedure might not be suitable for the clinical 
setting. 
An alternative approach has been to synthesis a copper-64 complex of 
polyethylenimine (PEI)-polyethylene glycol (PEG) (104). PEI it is widely used as a 
transfection agent so it was thought that the copper complex with this compound might 
efficiently deliver the radiocopper into cells. PEG was incorporated into the copper 
complex in order to decrease toxicity of PEI. Uptake and efflux in U87MG cells 









Cu-PTSM showed both greatest taken up into the cells and also highest 
percentage of retention (36%) in the labelled cells at 27 hr after labelling. Nevertheless 




Cu-PEI-PEG can be used for cell tracking 
and tumour imaging. However, these radiocopper complexes were unable to overcome 
the problem of low retention of the tracers in the labelled cells. 
Altogether, various copper complexes have been subjected to investigations and 
often offer excellent cell labelling yield but the efflux problem consistently remains. 
This might be caused by innate mechanism to control copper level in the cells, and is a 
severe limiting factor in the application of 
64
Cu for cell tracking.   
1.5 Indirect cell labelling  
Genetic engineering of reporter genes is performed under regulation of their 
promoters within either plasmid vectors or viral vectors (113) prior to introduction into 
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the targeted cells. Stable transfected cells are selected to prevent loss of reporter gene 
expression upon cell division. Then, probes (SPECT or PET isotopes) that specifically 
interact with proteins encoded by the reporter genes are used to image with SPECT or 
PET. Currently used reporter genes encode for three types of proteins including surface 
receptors, enzymes that react with radiotracer probes, or transporter proteins.  
1.5.1 Receptor gene, dopamine subtype 2 receptor (D2R) is one of interesting 







F–FESP) (115). However, D2R is highly expressed in 
brain generating high background leading to difficulty in discriminating between 
normal and reporter protein expression. Thus, mutation of this receptor gene has been 
developed to overcome this problem (115). 
Somatostatin receptor subtype 2 (SSTr2) is another potential reporter gene 
(116). Transduced cells produced SSTr2 which can bind to somatostatin analogs with 
high affinity. 
111
In-octreotide (approved for use in clinical practice) is used as a specific 
probe for imaging or labelling these reporter gene-expressing cells (116).  
However, the disadvantages of this technique still remain for examples, the 
encoding receptor protein must function as proper membrane protein and highly 
numbers of expressed receptors are needed. 
1.5.2 Reporter gene, an example of a reporter gene encoding an enzyme is 
herpes simplex virus type 1 thymidine kinase (HSV1-tk) and its mutant form, HSV1-




I-FIAU) was used to study 
tracking of T-lymphocytes that had been transduced with HSV1-tk (85). No alteration 
of cytotoxicity property of those cells was shown in the study. Tracking of Epstein - 
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Barr virus (EBV) specific T cells by 
131
I-FIAU both ex vivo and in vivo in mice has 
been investigated (117). Sequential imaging was performed at 1 hr, 1 day and 4 days 
after infusion of ex vivo labelled cells. The transduced cells accumulated 
131
I-FIAU and 
showed no loss of their function to eliminate specific tumour. However, resolution of 
imaging with I-131 is suboptimum because its emitted gamma energy is unsuitable 
with SPECT detector. 
  Recently, imaging of reporter gene-modified CD8+ cytotoxic T cells (CTLs 
containing IL-13 and HSV1-tk used for treating glioblastoma multiforme (GBM)) was 
successfully performed in patients (118). Three days after administration of modified 
cells, 
18
F-FHBG was used as a probe showing the localisation of engineered CTLs both 
in the tumour (in brain) and related organs. Furthermore, from a study by Su et al., not 
only can transduced cells be detected and imaged but it was also possible to estimate 
the number of cells by correlation between PET signal intensity and cell number (119). 
1.5.3 Genes encoding membrane transporter proteins have been investigated, 
including the human norepinephrine transporter (hNET) and sodium iodide symporter 
(NIS). NIS has been used as either a reporter gene or a therapeutic gene (120). It is a 
membrane glycoprotein that actively transports two sodium ions with one iodide ion 
across the cell membrane. Usually, NIS is highly expressed in thyroid cells and to a 
lesser extent in other organs including salivary gland and stomach. Not only I
-
 but also 










 can be cotransported with 
sodium ion (121) so cells transfected with NIS can be probed with a number of 
isotopes. However, because the organification processes that normally trap iodine in 
thyroid are absent in transfected cells, the probes are readily washed out. 
Recently, imaging of measles virus engineered to express NIS (MV-NIS) and 
MV-Edm (not containing NIS) in myeloma xenografts mice was performed with 
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radioiodide (122). On days 3 and 9 after viral administration, only MV-NIS showed 
uptake of the radiotracers. The higher concentration of radioiodide in the tumour in day 
9 might be due to proliferation of engineered virus causing an increase in NIS 
expression.      
Tracking of rat cardiac-derived stem cells (rCDCs) transfected with human NIS 
(hNIS) in heart was performed post transplantation for 10 days by using I-124 as a 
probe (123). Although adverse effects on cell viability and proliferation were not 
observed, low contrast ratio was evident. This may be from non-ideal imaging 
characteristics of I-124, which emits positron from only 26% of decays. Thus, other 







may be transported via NIS similarly to other 
anions (124). Its tetrahedral geometry with an anionic volume similar to iodide ion and 
pertechnetate suggest the possibility to use it as a probe for NIS (125). 
Recently, combinations of two or three reporter genes have been developed. 
Cao and co-worker utilised stable transfection of three reporter genes (monomeric red 
fluorescence (mrfp), firefly luciferase (fluc) and truncated thymidine kinase (ttk)) in 
murine embryonic stem cells (ES) to image ES transplantation in the myocardium 
(126). Significant differences in cell viability and proliferation between transfected 
cells and control cells were not observed by CyQuant cell proliferation assay and 
trypan blue exclusion assay for 4 weeks. Additionally, differentiation of transduced ES 
cells to cardiomyocytes showed the same rates as control cells in the in vitro studies. 
The bioluminescence and PET imaging demonstrated an increase in their signals during 
week 1 to 4, indicating that transduced ES cells survive and proliferate in vivo. 
An advantage of reporter gene labelling is that reporter proteins expressed by 
stable transfected cells are not diluted over cell divisions or cell proliferations. 
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Radiotracer probes are able to repeat detection of cell tracking over time. Furthermore, 
detected signals are only generated from viable transduced cells.  However, there are 
disadvantages of reporter genes for example reporter genes cause immunogenic 
responses or other toxicities. Reporter gene silencing and perturbation of transduced 
cell behaviour may occur. In addition, transfection stability needs to be improved to 
obtain stable transfected cells.  
 
Conclusion 
 In conclusion, long lived PET radiotracers which offer efficient intracellular 
uptake and remain stably associated with the labelled cells over a sustained period of 
time would be desirable. New direct labelling tracers have been sought in order to 
implement into clinical routine services to use PET to improve quality of the diagnostic 
use of radiolabelled cells or for the advanced applications of cell labelling and cell 
trafficking, but satisfactory agents are not yet available. This thesis assesses two 













 Various applications of cells labelling, such as following autologous 
radiolabelling blood components, stem cells and immune cells), require the half life of 
the radiotracers for labelling cells to be long enough to allow tracking labelled cells for 
period of times.  Detecting particularly small lesions or tracking low numbers of 
radiolabelled cells poses particular challenges for cell labelling. Comparing positron 
emission radiotracers to those of single photon emission for tracking labelled cells, 
PET scanning is expected to provide better resolution and quantification of the amount 
of radiolabelled cells in vivo. The intermediate long lived PET radionuclide, 
64
Cu is 
now increasingly produced in a number of cyclotron centres may provide a solution to 
the half life and positron emission requirement. It emits suitable low-energy positrons 
for PET detector with the physical half life of 12.7 hr. Therefore 
64
Cu is an attractive 
PET radioisotope for in vivo tracking of labelled cells. Related copper information in 
the aspects of its chemistry, metabolism, production and chelators for copper was 
summarised as follows.  
2.1.1 Chemistry of Copper 
Copper in aqueous solution usually exists in one of three oxidation states (I, II 
and III) of which Cu(I)  and Cu(II) are more usual. Cu(I) can form complexes with 
thioethers, phosphines, nitriles, isonitriles, nitriles, cyanide, iodide and thiolates (105).
 
Some ligands (thiolates, phosphines and iodide) also act as reducing agents to reduce 
Cu(II) (e.g. in copper chloride) to Cu(I). Cu(II) on the other hand shows a preference to 
react with amines, imines and H2O. These groups have less polarisation and bind less 
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covalently compared to those groups that bind to Cu(I) (105). Cu(II)  forms various 
type of complexes  such as square planar and  octahedral. The preference for oxidation 
states depends on the ligand types. Bifunctional chelators (e.g. macrocycles, aromatic 
macrocycles) play an important role in stabilising Cu(II) in copper 
radiopharmaceuticals. The highest oxidation state of copper, Cu(III), needs strong -
donating ligands, typically deprotonated amide groups. 
2.1.2 Metabolism of Copper 
Most plasma copper binds to proteins such as albumin, ceruloplasmin, 
transcuprein and metalloenzymes, and to amino acids especially histidine. Copper(II) is 
found to associate with transport proteins (albumin and transcuprein) and then transfer 
to liver cells via small amino acid (histidine) complexes resulting in rapid copper 
clearance from blood. Liver synthesises ceruloplasmin and metallothionein from taken 
up copper. Thus, copper exists in blood circulation in form of ceruloplasmin (127). 
Although copper is cleared rapidly from blood, the retention time of radiocopper in 
circulation can be increased in the presence of bifunctional chelators.  
2.1.3 Copper production 















Cu) or a generator (
62
Cu).  In reactor production, both direct 
(known as thermal neutron reaction (
63
Cu (n, )) and fast neutron reaction (64Zn(n, p)) 
generate copper-64 with varying specific activity. McCarthy et al. reported a method to 
produce copper-64 using enriched 
64
Ni plated as a target from a small biomedical 
cyclotron (128). Ion exchange chromatography was used to separate the copper-64 
product from the nickel target. This method showed high specific activity and purity of 
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copper-64. Moreover, the nickel target can be reused and the recovery yield of 
64
Ni was 
around 90 %. 
 2.1.4 Chelators for Copper 
In order to bind or incorporate copper to cells or interesting tissues, appropriate 
chelator ligands are required either to ensure kinetic stability of complexes (when 
radiolabelling proteins for example) or to exploit molecular properties of copper-
chelates complexes such as redox. Targeting biomolecules such as proteins and 
antibodies requires bifunctional chelators (BFCs) to stabilize complexes with 
radiocopper in vivo (129).  
The functions of BFCs (Figure 2.1) are coordination with metal ions and 
covalent binding to the targeting molecules. Various types of BFCs for copper 
radionuclides have been investigated. 
  
                            
                        Figure 2.1: Diagram of bifunctional chelator function 
Acyclic polyamine carboxylate ligands and their derivatives including DTPA 
and EDTA have been evaluated. Studies of serum stabilities of radiocopper complexes 
were performed and the results indicated a rapid dissociation of copper. Only 35% and 
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18% of the original copper complexes which remained intact in human serum after 
three days (130). 
Development of macrocyclic polyaminocarboxylates (TETA, DOTA and 
NOTA) overcame the problem of instability in serum. BFCs in this group can enhance 
stability of copper complexes and are widely used to conjugate with biomolecules (e.g. 
antibodies, peptides) (131). Alternatively, cyclic polyamines (e.g. cyclam) rapidly form 
complexes with copper and show kinetic inertness in physiologic conditions. Other 
ligands have been studied such as N2O2 Schiff-base derivatives (for brain imaging), and 
diphosphine complexes (105).  
Bis (thiosemicarbazones) (BTSCs) such as ATSM, PTSM and GTSM were 
described previously in Chapter 1, section 1.4.3. In brief, owing to instability of copper 
BTSCs complexes, BTSCs are unsuitable for bifunction chelator purpose. On the other 
hand the labile property of those lipophilic copper complexes is an advantage for 
delivering radiocopper into the cells because the complexes are reduced inside cells 
leading to release of copper which becomes bound to intracellular molecules (101). The 
selectivity of these copper complexes taken up by the cells is dependent on their redox 
potential. As summarised previously, the results of the uptake of copper BTSCs 
complexes indicated that GTSM was efficiently extracted into cells. Then, Cu-GTSM 
complex might be suitable as a tracer for labelling cells. 
Sampson and Solanki studied lipophilic Tc-99m complexes of dithiocarbamate 
(widely used as metals chelator) for labelling leukocytes (39). Not only was excellent 
uptake of the radiotracer in white blood cells observed, but also stability in the labelled 
cells was higher than 75% after labelling for 4 hr. So, dithicarbamate ligands may also 





The aims in this section were to synthesise a range of lipophilic 
64
Cu complexes 
with bis(thiosemicarbazone) and dithiocarbamate ligands, designed to enter cells by 
virtue of their lipophilicity and dissociate bioreductively inside cells. Characterisation 
of the radiotracer and optimisation of the amount of ligand for synthesis the 
radiocomplex was carried out. 
In addition, the studies aimed to evaluate the copper complexes as cell labelling 
agents. Experiments were conducted to determine the rate and efficiency of cell 
labelling with 
64
Cu BTSC and 
64
Cu DTC complexes, and to determine the rate of efflux 
of radioactivity from cells labelled with these tracers and hence evaluate their potential 
as radiotracers for cell tracking over hours and days. Comparison of labelling 
efficiencies and cellular retention in various types of cells among tracers was 
performed in order to seek out the tracers best suited for labelling cells. 
 
2.3 Methods 
2.3.1 Radiolabelling of 
64
Cu complexes 
In order to synthesis 
64
Cu BTSC complexes and 
64





Cu (DEDTC)2 were chosen as the representative for each group of ligand. 
64
Cu-PTSM complex was synthesised as follows. 
64
Cu was kindly provided by Dr. 
Karen Shaw and was produced at the PET Centre, St Thomas‟ Hospital, London (132). 
64
Cu was produced from enriched 
64
Ni bombarded with 11 MeV protons. 
64
Cu was 
dissolved from the 
64
Ni target with 9 M HCl and then purified using a column packed 
with AG1-8X anion exchange resin (Bio-Rad, UK). 
64
Cu was eluted from the column 
with HCl. So, 
64
Cu was provided in the form of 
64
CuCl2 (typically the fractions 
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contained 1 M HCl). PTSM was kindly provided by Prof. Philip Blower, Department 
of Imaging Sciences and Biomedical Engineering, King‟s College London, London 
(133). PTSM was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 1 
mg/ml. Ten l of PTSM solution was added to 64CuCl2 (activity between 50 MBq to 80 
MBq) and deionised water was used to make a final volume to around 1 ml before 
gentle shaking to mix the reaction solution. The mixture was incubated at the room 
temperature for 15 min. A SEP-PAK® C18 Classic cartridge (Waters, UK) was used 
to purify 
64
Cu-PTSM. The cartridge had been previously equilibrated with 3 ml of 
absolute ethanol followed by 3 ml of deionised water. The solution was then filtered 
through the pre-equilibrated C18 cartridge. Five ml of water was washed through the 




Cu-PTSM was eluted with 0.5 ml of absolute 
ethanol. The activity of 
64
Cu-PTSM was measured using radioisotope dose calibrator 
(CRC-25R Capintec, USA). 
Apart from PTSM, other BTSC ligands; PTS, GTS and GTSM kindly provided 
from Prof. Philip Blower were chosen to synthesise radiocopper complexes. The 




For labelling of 
64





buffered with 2 equivalent volumes of 3 M sodium acetate to reach pH of 6.5 – 7.0. 
The amount of DEDTC was optimised to achieve acceptable radiolabelling efficiency 
with the lowest amount of ligand. A solution of sodium diethyldithiocarbamate 
trihydrate ((C2H5)2NCS2Na.3H2O) (Sigma, UK) was prepared at concentrations of 1, 
0.1, 0.01, 0.001 mg/ml in 0.9% normal saline. Twenty l of the solution for each 
concentration was added (corresponding to 20 g, 2 g, 0.2 g and 0.02 g of 
DEDTC) and gently stirred with the 
64




Cu (DEDTC)2 was purified by SEP-PAK® C18 column with the same procedure for 
64
Cu-PTSM as described above. 
Other 
64
Cu DTC complexes e.g. dimethyldithiocarbamate (DMDTC) and 
dipropyldithiocarbamate (DPDTC) were synthesised in order to evaluate their potential 
for cell labelling. The optimised amount of DEDTC and synthesis procedure for 
64
Cu 
(DEDTC)2 were applied to synthesise the other 
64





Cu (DPDTC)2).  
2.3.2 Thin layer chromatography (TLC) and high performance liquid 
chromatography (HPLC) of copper diethydithiocarbamate 




Cu (DEDTC)2 in HPLC and TLC 
systems, cold copper diethyldithiocarbamate (Cu (DEDTC)2) was produced from the 
reaction between cupric sulphate (CuSO4.5H2O) (Sigma, USA) and sodium 
diethyldithiocarbamate trihydrate with a molar ratio 1:2, respectively. A solution of 
125.5 mM sodium diethyldithiocarbamate trihydrate and 63 mM cupric sulphate was 
freshly prepared. The copper solution was added dropwise to the stirred sodium 
diethyldithiocarbamate solution. The solution was continuously stirred for 1 hr. 
Crystals of the product Cu (DEDTC)2 were filtered, washed with water then dried in a 
50
o
C oven for 5 hr. Then 1 mg of Cu (DEDTC)2 (black precipitate) was dissolved in 5 
ml methanol. One microlitre of this solution was spotted on silica gel 60 F254 strips (1 
cm x 10 cm), (TLC-SG), (Merck, Germany) as a stationary phase, ethanol was used as 
a mobile phase. The Rf of the copper complex in this system was determined. 
Meanwhile, copper sulphate (CuSO4) solution was used as a standard for Rf of free 
copper in the same TLC system. 
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Cu acetate were analysed by reverse phase HPLC (RP-HPLC) using 
a C18 column (Agilent Eclipse XDB-C18, USA). The mobile phase was prepared as a 
gradient consisting of water with 0.1% trifluoroacetic acid (TFA) as a solvent A and 
acetonitrile containing 0.1% TFA as solvent B with a flow rate of 1 ml/min.  The 
gradient was as follows: solvent A: solvent B as 90:10 % at start to 5:95 % over 15 
min, hold for 15 min and then reverse to 90:10 % (A:B) over 5 min. The UV detection 
wavelength was set at 220 nm in series with radio-detector.  
2.3.3 Determination of radiolabelling efficiency and radiochemical purity 
Various amount of DEDTC (as mentioned in section 2.3.1) were used to 
synthesise 
64
Cu (DEDTC)2 and then radiolabelling efficiency was examined by radio-
TLC using TLC-SG as the stationary phase and absolute ethanol as the mobile phase 
prior to purifying with SEP-PAK® C18 column. Radiochemical purities of the purified 
radiocopper complexes were also assessed by radio-TLC, using the same TLC system. 
  One microlitre of the synthesised solution and 
64
Cu acetate was applied onto a 
TLC strip (1 cm x 10 cm) at 0.5 cm from the edge and the strip was placed in ethanol 
(lower than 0.5 cm in depth). The mobile phase was allowed to run to reach 9.50 cm of 
the strip. It was removed and dried in air. The radio-chromatogram of the TLC strip 
was then used to determine radiolabelling efficiency or radiochemical purity using a 
TLC scanner (LabLogic, UK) fitted with a β-/+ detector (B-FC-3600) using Laura (v. 
4.0.3.75) software (LabLogic, UK). The radiochemical purities of the radiocopper 
complexes were greater than 95% in all the subsequent experiments. In addition, to 
evaluate shelf life of 
64
Cu (DEDTC)2, quality control of this tracer was performed 24 
hr after preparation. 
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2.3.4 Cell culture 
Mouse macrophage cell line J774, human colorectal cancer cell line HCT 116, 
and murine multiple myeloma cell line eGFP-5T33 were chosen for the in vitro studies 
in this section. J774 cells were kindly provided by Dr. Helen Collins, Department of 
Infectious Diseases, King‟s College London and eGFP-5T33 cells were provided by Dr 
Yolanda Calle (University of Roehampton (former lecturer at King‟s College London; 
further information about this cell line is provided in chapter 4)) and HCT 116 cell line 
was purchased from European Collection of Cell Cultures (ECACC). J774 and HCT 
116 cells were cultured as adhesion cells. J774 was grown in high glucose (4.5 g/L), 
Dulbecco‟s Modified Eagle‟s Medium (DMEM) supplemented with 2 mM L-
glutamine, penicillin/streptomycin (5 ml/500 ml of 5000 UI/ ml pen /5000 g/ml 
strep.), 1 mM sodium pyruvate, 10 mM HEPES and 10 % foetal bovine serum by 
volume, under humidified atmosphere at 37
o
C with 5% CO2. HCT 116 cells were 
cultured in McCoy‟s 5a supplemented with 2 mM L-glutamine, penicillin/streptomycin 
(5 ml/500 ml of 5000 UI/ ml pen./5000 g/ml strep.) and 10 % foetal bovine serum. 
eGFP-5T33 cells were grown in suspension culture in RPMI 1640 supplemented with 
10% foetal bovine serum, L-glutamine and penicillin/streptomycin. Cells were semi-
continuously cultured in humidified 37
o
C with 5% CO2. Cells were subcultured by 
transferring cell suspensions to new 50 ml Falcon tubes followed by centrifugation at 
2000 RPM for 5 min. The supernatant was discarded and the cell pellet was 
resuspended in fresh culture medium and transferred to new culture flask. In order to 
prepare cells for particular experiments, cell pellets were washed with PBS twice 
before counting cell numbers for preparing cell concentrations required for each study.   
Radiolabelling of J774 and HCT 116 cells was investigated in 24 well plates. 
One day before the experiments, J774 and HCT 116 cells were harvested and seeded in 
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24 well plates with a density of 5 x 10
5
 cells and 3 x 10
5
 cells per well in 0.5 ml 
medium, respectively. 
Radiolabelling of J774 and eGFP-5T33 cells was also studied in the glass 
tubes. On the experiment day, J774 cells were harvested by scraping and resuspended 
in the serum free medium. Washed eGFP-5T33 cells were prepared in serum free 
medium. Cells were counted and then 1 x 10
6
 cells of either type in 450 l serum free 
medium were dispensed into the glass tubes.  
2.3.5 Radiolabelling the complexes of 
64
Cu bis(thiosemicarbazones) (BTSCs) and 
64
Cu dithiocarbamate (DTC) analogues for in vitro studies  
 BTSC ligands, PTS, PTSM, GTS and GTSM were provided by Prof. Philip 
Blower (133) and dipropyldithiocarbamate (DPDTC) was synthesised and provided by 
Dr. David Berry while dimethyldithiocarbamate (DMDTC) and diethyldithiocarbamate 
(DEDTC) were purchased from Sigma, USA.  
All of BTSC ligands and DTC analogues were labelled with 
64
Cu and evaluated 
for intracellular accumulation and retention. The labelling and quality control methods 




Cu acetate was used to synthesise 
the complexes with BTSCs and DTCs, respectively. Ten microlitres of 1 mg/ml 
BTSCs in DMSO were added to 
64
CuCl2 and the product was purified with SEP-
PAK® C18 column. The 
64
Cu BTSC complexes were eluted with absolute ethanol. 
Meanwhile 20 l of 1 mg/ml of DTCs in 0.9% saline were added to 64Cu acetate and 
resulting complexes were purified with pre-equilibrated SEP-PAK® C18 cartridge 
(with ethanol). The purified 
64
Cu complexes were eluted from the cartridge using 
absolute ethanol. Radiochemical purity (RCP) of the 
64
Cu complexes was examined 
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with the TLC system previously described. RCP of the radiocopper complexes used in 
the following experiments was always greater than 95%. 
2.3.6 In vitro cell uptake of 
64
Cu complexes  
This study aimed to determine the intracellular uptake of radiocopper 
complexes. Two different procedures were evaluated to determine the uptake as 
described below. 
2.3.6.1 Reaction in 24 well plates with J774 cells and HCT 116 cells 
The cell cultures in 24 well plates prepared as described in the previous section 
were used for radiotracer uptake study. Protocols for cell uptake were as follows. The 
cultured medium was removed from the wells and cells were washed twice with 
warmed Hanks‟ balanced salt solution (HBSS) (with calcium and magnesium). The 




Cu (DEDTC)2) was 
measured in a dose calibrator and each sample was diluted in warmed HBSS to a final 
concentration of 0.2 MBq per ml (containing ethanol less than 1% after dilution). The 
radiotracer (0.1 MBq, 500 µl) was added to each well and incubated at 37
o
C with 5% 
CO2.  The uptake was evaluated after incubation for 1, 5, 10, 20, 40, 60 and 120 min 
(each experiment was done in triplicate).  At each time point, the supernatant was 
removed from a well and the adherent cells were washed twice with 0.5 ml cold HBSS. 
Both supernatant and washing buffer were collected. Subsequently, cells were 
disrupted and collected by incubation with 500 µl of 1 M sodium hydroxide (NaOH) 
solution for 10 min. These cell lysates and supernatants from each well were measured 
by gamma counter (1282 Compugamma, LKB Wallac, Australia) as counts per minute 
(CPM).   Following counting activity, the protein content of lysed cells (Pr) was 
assayed by using BCA protein assay kit. The cellular uptake was calculated as follows:  
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The cellular uptake/g protein = ((CPMcell / (CPMcell + CPMsup)*100)/Pr). 
Where     CPMcell   = the count rate in the cells 
                CPMsup  = the count rate in the corresponding supernatant 
                Pr           = the protein content of lysed cells (microgram) 
2.3.6.2 Reaction in glass test tubes with J774 cells and eGFP-5T33 cells 
 In this section, intracellular uptake of the 
64
Cu complexes was investigated in 
the tubes using the procedure described as follows. 
 The stock solutions of 
64
Cu BTSCs and 
64
Cu DTCs complexes in ethanol were 
prepared by diluting the radiocopper complexes to a concentration of 2 MBq/ml (0.1 
MBq per 50 l) with serum free medium. Then 50 l of the stock solution was added 
to the test tube containing 1 x 10
6
 cells in 450 l (serum free medium) in triplicate for 
each time point. The reactions were incubated at the room temperature. The 
intracellular accumulations by the cells were determined after adding the radiocopper 
tracers for 1, 15, 30, 45 and 60 min. The 
64







Cu-GTSM, respectively) and 
64
Cu (DTC) 
complexes of DMDTC and DEDTC (
64
Cu (DMDTC)2 and 
64
Cu (DPDTC)2, 





Cu (DPDTC)2 were also investigated in J774 cells. At the chosen time point, the 
reaction tube was centrifuged at 2500 RPM for 5 min and then 450 l of the 
supernatant was pipetted into a new tube. The count rate of the cell pellets and their 
corresponding supernatants were counted in gamma counter. The actual count rate in 
the cells was corrected for the count rate of the residual 50 l of supernatant. The 
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percentage of radiotracer uptake in the cells was calculated as shown in the equation as 
follows: 
% uptake in the cells = (CPMact cell *100)/ (CPMcell + CPMsup) 
    CPMact cell  = CPMcell – ((CPMsup * 50)/450) 
   where  CPMact cell  = actual count rate of the cell pellet corrected with the 
count rate of 50 l residual of supernatant  
          CPMcell  = count rate of the cell pellet 
          CPMsup  = count rate of the supernatant 
2.3.7 Measurement amount of protein by BCA assay 
 Since the cells subjected for the uptake experiments were previously seeded 
into 24 well plate for 1 day before the study, growth and replication causes the number 
of cells to increase to a degree that varies among samples. Therefore the amount of 
protein in the taken up cells was measured after radiolabelling in order to normalise the 
results of accumulation of the radiotracers in the cells prior to comparing the uptake 
among samples. For this purpose we used a commercial bicinchoninic acid (BCA) 
protein assay to measure the protein content in the cells. The BCA assay is a 
colorimetric technique based on the Biuret reaction. Cu
2+
 is reduced to Cu
+
 and then 
reacts with BCA solution resulting in a purple complex the colour of which is 
proportional to the amount of protein in the sample. The optical density of this 
complex can be measured at 562 nm. The amount of protein in the sample is 
determined by comparing with protein standards. Following the uptake experiments in 
the plates, solutions of cells lysates were subjected to assay with a Novagen® BCA 
protein assay kit (Merck, Germany) following the manufacturer‟s standard procedure. 
60 
 
A range of protein standards was prepared by dilution in PBS from a stock solution of 
2 mg/ml bovine serum albumin (BSA). Aliquots of 25 l of the protein standards and 
samples were loaded into a 96 well plate in triplicate. 200 µl of BCA solution was then 
added to each well. Absorbance was measured at 562 nm, after incubation for 30 min 
at 37
o
C, using a multiwell plate reader. Averages of triplicate samples and standards 
were calculated and the concentration of each sample was determined by comparison 
to a BSA standard curve. 




Cu (DEDTC)2 were investigated for binding of radiotracers 
to the plastic 24 well plate. The tracer solutions (0.5 ml of 0.2 MBq/ml in HBSS) were 
incubated in the plates without cells.  At the chosen time point, tracer solutions were 
removed and 500 l of HBSS was used to wash each well twice. Both removed tracer 
and washing solutions were pooled together. In case of 
64
Cu (DEDTC)2, 0.5 ml of 1M 
NaOH was added and incubated for 10 min. NaOH solution was removed and 
collected separately. All samples were quantified by gamma counter to determine the 
percentage of tracer attached to the plate.  
Since the cellular uptake of the radiotracers with some cell lines was carried out 
in glass tubes, we also determined the degree of binding between tracers and these test 
tubes. Cell free media were prepared in the reaction tubes then the radiocopper tracers 
were diluted and added to the tubes in the same manner as for the cell uptake 
experiments. The mixture was incubated and removed from the tubes at the chosen 
time points then collecting into a new tube. 0.5 ml PBS was used to wash the tube 
twice and the washing buffers were added into the collected supernatant tube. The 
activities in the tubes and the supernatant fractions were counted by gamma counter. 
The percentages of radiotracers bound to the tubes were calculated. 
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2.3.9 Efflux of radiotracers 
From the uptake studies evaluated in multiwell plates, to study the efflux of 
64
Cu-PTSM from various cell lines, the experiments were carried out in the same 
manner as cell uptake experiment. Cells in each well were incubated with 0.1 MBq 
tracer in 0.5 ml of HBSS for 30 min to allow cells to take up the tracer. Radioactive 
solution was removed before washing the cells with HBSS twice. New tracer-free 
media were added and incubated at 37
o
C with 5% CO2 for 0.5, 1, 2, 3, 4, 6, 20 and 24 
hr.  The efflux media of each sample were collected together with their washing buffer 
(0.5 ml HBSS, 2 times) in different time points.  Cells were lysed and harvested in 0.5 
ml of 1 M NaOH. The count rate of the activity in cells (CPMcell) and in efflux media 
(CPMeff) at each time point was determined by gamma counter. The percentage of 
radioactivity retention at each time point was calculated as follows: 
   Percentage of radioactivity retention in the cell = (CPMcell / (CPMcell + CPMeff))*100 
    where    CPMcell = counts per minute of the cells 
  CPMeff = counts per minute of the correspondent efflux media 
 Efflux studies in cells labelled in test tubes rather than multiwell plates were 
carried out as follows. On the day of experiment, 1 x 10
6
 J774 cells in depleted serum 
medium were dispensing into the reaction tube and for the uptake, 0.1 MBq of the 
64
Cu 
BTSC complexes (PTS, PTSM, GTS and GTSM) and DTC complexes (DMDTC, 
DEDTC and DPDTC) were added and serum free medium was added to reach a final 
volume of 500 l then incubation the reaction mixture at room temperature for 30 min. 
The supernatants were removed and the residual radiotracers were eliminated by 
washing with 500 l PBS twice before fresh culture media were added to the tubes.  
The percentage of the remaining activity in the cells was examined at 1 hr, 2 hr, 3 hr, 4 
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hr and 20 hr after the washing. The retained activities in the cells and the effluxed 









Cu (DEDTC)2 were also determined in 
eGFP-5T33 cells at 1 hr, 2 hr, 3 hr and 4 hr post the uptake.   
 
2.4 Results 





Cu-PTSM was synthesised and purified with SEP-PAK® C18 column prior 
to determining the radiochemical purity. The quality control performed with silica gel 
TLC constantly showed with Rf around 0.7 (Figure 2.2).     
 
                                 
 
Figure 2.2: Radiochromatogram of purified
 64
Cu-PTSM with silica gel TLC plate  
2.4.2 Radiolabelling and quality control of 
64
Cu (DEDTC)2 
 Chromatograms of cold Cu (DEDTC)2 performed with TLC-SG showed the Rf 
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The labelling efficiency of 
64
Cu (DEDTC)2 was 100 % (Rf  around 0.6); no free 
copper was detected at the origin when using 20 g of DEDTC as shown in Figure 2.3.  
This complex remains stable up to 24 hr after preparation (Figure 2.4).          
 
    
 
Figure 2.3: Labelling efficiency of 
64
Cu (DEDTC)2 (before purification, using 
DEDTC 20 g) with silica gel TLC plate. 
                                           
          
 
Figure 2.4: Radiochromatogram of 
64
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Apart from pilot concentration (20 g of 64Cu (DEDTC)2, the radiochemical 
testing results of 
64
Cu (DEDTC)2 synthesised from 2 g, 0.2 g and 0.02  g of 
DEDTC were illustrated in Figure 2.5 and 2.6.  These results indicated that impurity of 
complex was detected when using 2 g DEDTC (Figure 2.5), and only free 64Cu was 
detected when concentration of DEDTC was 0.2 g /ml or below (Figure 2.6).   
 
                                       
 
 Figure 2.5: Radiochromatogram of 
64
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  (A)  
 
    
                (B) 
Figure 2.6: Radiochromatogram after incubation of 
64
Cu with 0.2 g (A) and 0.02 
g  (B) of DEDTC. No labelled complex is detected under these conditions.  
2.4.3 HPLC of Cu (DEDTC)2 
The HPLC results of sodium diethyldithiocarbamate and cold Cu (DEDTC)2 
using UV detector at wavelength 220 nm showed the main peaks at around 11 and 15.5 
min, respectively, as shown in Figure 2.7. 
64
Cu (DEDTC)2 was evaluated both in the 
gamma detector and the UV detector. The peak of 
64
Cu (DEDTC)2 showed only one 
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observed as shown in Figure 2.8. For 
64
Cu acetate, the gamma peak occurred at 2 min 
similar to peak monitored by UV detector as shown in Figure 2.9.   
 
                             
       (A) 
 
                                
                (B)  
Figure 2.7: HPLC of sodium DEDTC (A) and cold Cu (DEDTC)2 (B) with UV 
detector at 220 nm, show peak at 11 and 15.5 min, respectively. 
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(A) 
 
                            
    (B) 
Figure 2.8: HPLC of 
64
Cu (DEDTC)2 monitored by gamma detector (A) and UV 
detector at 220 nm (B). In A, single activity peak of 
64
Cu was detected at nearly 16 
min which correlated to peak in UV detector of cold Cu (DEDTC)2.    
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        (A) 
 
                              
        (B) 
Figure 2.9: HPLC of 
64
Cu acetate monitored by gamma detector (A) and UV 
detector at 220 nm (B). 
64
Cu acetate was detected by gamma detector at 2 minutes.  
2.4.4 Cell uptake of radiopharmaceuticals   
In this section, cell labelling experiments conducted in 24 well plates are 
reported separately from those conducted in glass tubes. Radiopharmaceutical uptake 





Cu PTSM and 64Cu (DEDTC)2. Uptake of each tracer in cells was 
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compared with and without normalisation against protein content shown in Figure 
2.10, 2.11 and 2.12. 
                    
      (A) 
                     
      (B) 
 
Figure 2.10: The percentage uptake of 
64
CuCl2 into J774 cells and HCT 116 cells 
without (A) and with normalisation against microgram of protein (B), 

















































                    
     (A) 
 
                     
     (B) 
Figure 2.11: The percentage uptake of 
64
Cu PTSM into J774 cells and HCT 116 
cells without (A) and with normalised with microgram of protein (B), respectively.  

















































                   
                                                                      (A) 
                   
      (B) 
Figure 2.12: The percentage uptake of 
64
Cu (DEDTC)2 into J774 cells and HCT 
116 cells without (A) and with normalising against microgram of protein (B), 



















































Cell labelling experiments in glass tubes were performed with a wider range of 
64
Cu (BTSC) and 
64
Cu (DTC)2 complexes in J774 suspension cells and in eGFP-5T33 
myeloma cells. Results are presented in Figures 2.13 - 2.16, respectively.  
 
              
Figure 2.13: The percentage uptake of the 
64
Cu (BTSC)s into J774 cells. The data 

























      
 
        (A) 
 
 (B) 
Figure 2.14: The percentage uptake of the complexes of 
64
Cu (DTC)2 complexes 
into J774 cells, (A) 
64
Cu (DMDTC)2 and 
64
Cu (DMDTC)2  (B) 
64
Cu (DEDTC)2. 












































              
Figure 2.15: The percentage uptake of the complexes of 
64
Cu (BTSC) complexes 
into eGFP-5T33 cells. The data values were mean ± SD of triplicate samples from 1 
experiment. 
                
Figure 2.16: The percentage uptake of the 
64
Cu (DTC)2 complexes into eGFP-
5T33 cells. The data values are mean ± SD of triplicate samples from 1 experiment. 
The percentage uptake of 
64













































2.4.5 Plasticware testing 
The degree of tracer attached to culture plates and glass tubes was investigated 
in order to ensure that measured activity from the cell lysates represented activity that 
had been taken up by the cells ant not merely bound to the plastic or glass. Tracers 
were added into cell free culture plate and were removed from plate at 20, 40, 60 and 
120 min for 
64
Cu-PTSM and at 20, 60 and 120 min for 
64
Cu (DEDTC)2. The result 
showed negligibly activity of 
64
Cu-PTSM bound to the plate over period of the 
experiments. 
64
Cu (DEDTC)2 were significantly attached to cultured plate as shown in 
Figure 2.17. To determine whether this tracer can be recovered from plate with NaOH, 
radioactivity in the removed NaOH was measured and percentage of removal was 
calculated (also in Figure 2.17). Evaluation of adsorbable activity among the 
radiotracers to the glass tubes was illustrated in the graph (Figure 2.18).  
 
 
Figure 2.17: The percentage of 
64
Cu (DEDTC)2 bound to plastic plate, at 20, 60 

































Figure 2.18: The percentage of 
64
Cu complexes of BTSCs and DTCs bound to test 
tube, at 1, 15, 30, 45 and 60 min.  
2.4.6 Efflux experiment 
To study the efflux rate from cells after 
64
Cu-PTSM labelling, the radioactive 
activity leakage in the normal culture medium from each cell line was measured and 
the percentage of tracer retention inside the cells at the particular time point was 
calculated. 
64
Cu-PTSM was rapidly washed out from the cell lines: within 2 hr only 
half of activity remained in the J774 cells. After 24 hr, approximately 60% of the tracer 
had leaked from J774 cells. For HCT 116 cells, around 40% was eluted in the tracer-
free medium post incubation for 6 hr while approximately 50% of activity remained in 
the cells 24 hr after labelling as shown in Figure 2.19. The activity effluxed from J774 
and HCT 116 cells after labelling with 
64
Cu (DEDTC)2 at 24 hr was approximately 




































    
Figure 2.19: Percentage retention of 
64
Cu-PTSM within J774 cells and HCT 116 
cells during 24 hr, after labelling for 0.5 hr and washing (mean ± SD from 3 
experiments) 
 
                  
Figure 2.20: Percentage retention of 
64
Cu (DEDTC)2 within J774 cells and HCT 



















































The efflux rates of the 
64
Cu (BTSC) complexes and 
64
Cu (DTC)2 complexes 
employed in J774 cells are shown in Figures 2.21 and 2.22. The retained activity of all 
64
Cu (BTSC) complexes in J774 cells was lower than 30% at 20 hr after incubation 
cells in the tracer free medium (Figure 2.21). Approximately 40% of 
64
Cu (DTC)2 
complexes was retained within the cells at 4 hr, decreasing to 16% and 28% at 20 hr 
post labelling (Figure 2.22). 
              
 
Figure 2.21: Percentage retention of the complexes of 
64
Cu (BTSC)s within J774 
cells, are compared after incubation in radioactivity-free medium for 1 hr, 2 hr, 3 hr, 4 































Figure 2.22: Percentage retention of the complexes of 
64
Cu (DTC)2 complexes and 
64
Cu-PTSM within J774 cells after incubation in radioactivity-free medium for 1 



























In eGFP-5T33 efflux was only measured up to 4 hr after completion of cell 
labelling. The results showed that greater than 60% of the activity had leaked from the 
cells by 4 hr post incubation with the fresh medium as shown in Figure 2.23.  
 
 
Figure 2.23: Percentage retention of the complexes of 
64
Cu (BTSC) complexes and 
64
Cu (DEDTC)2 within eGFP-5T33 cells, are compared after incubating for 1 hr, 2 
hr, 3 hr and 4 hr in radioactivity-free medium. The data values are mean ± SD of 
triplicate samples from 1 experiment. 
 
2.5 Discussion 
 The TLC radiochromatogram results of 
64
Cu-PTSM showed high purity 
(100%) which was reproducible in every preparation, showing that the preparation of 
the labelled complex is simple and reliable. Nevertheless, quality control by TLC was 
performed before starting new biological experiment to ensure that there would be no 


























In order to validate the result of radiolabelling of novel radiotracers, the TLC and 
HPLC chromatogram of all synthesised radiotracers have to be compared with the 
corresponding cold complex and cold copper salt. The TLC chromatogram of copper 
sulphate and Cu (DEDTC)2 complex showed the Rf values of free copper and the 
complex were zero and 0.6, respectively. Radiochromatograms of 
64
Cu (DEDTC)2 (20 
g of DEDTC) in the same TLC system were analysed. The single radioative peak 
showed the same Rf of 0.6 as cold copper complex. No peak corresponding to free 
copper (Rf = 0) was observed suggesting a radiochemical purity of 100% for 
64
Cu 
(DEDTC)2. In addition, this complex has a shelf life up to 24 hr after preparation as 
verified by TLC.  
The TLC chromatogram of 
64
Cu (DEDTC)2 showed high labelling yield, 
however, radiochemical impurities were demonstrated when the amount of DEDTC 
decreased to 2 g. A mass of DEDTC less than 2 g (0.2 and 0.02 g) was not enough 
to label efficiently with radiocopper as shown in Figure 2.6. Therefore, the optimum 
amount of sodium diethyldithiocarbamate selected for production of 
64
Cu (DEDTC)2 
was 20 g.  
Apart from TLC, HPLC analysis of sodium diethyl DTC and the cold and hot 
copper DTC complex was performed. The HPLC chromatogram using the UV detector 
(at 220 nm) showed the retention time of sodium diethyldithiocarbamate and copper 
complex at 11 and 15.5 min, respectively. The hot copper complex exhibited only one 
radioactive peak at 16 min while no obvious UV peak was detected at 220 nm. It is 
likely that of the amount of the radiocomplex is lower than detectable by the UV 
detector. The gamma detector detects the activity peak of radioactive product about 10 
sec later than the UV detector because of the distance between the detectors. 
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Therefore, the peak in gamma detector was related to peak of cold Cu (DEDTC)2 in 
UV detector (at 15.5 min) suggesting that this peak was 
64
Cu (DEDTC)2.  
TLC is suggested as the routine QC method to analyse the radiopharmaceutical 
product in every preparation rather than HPLC because of reliable determination 
results and rapid procedure that is suitable for routine studies. 







Cu (DEDTC)2  in J774 and HCT116 cells. 
64
CuCl2 was used as a control 
to determine the uptake of free 
64
Cu by the cells. In both cell types, an insignificant 
percentage uptake of 
64
CuCl2 was observed over the first hour of incubation before 
slightly increasing by two hours to around 15% and 7% for J774 and HCT 116, 
respectively. This was unexpected because 
64
CuCl2 is not lipophilic and should not 
diffuse non-specifically through cell membranes. Thus, there is a possibility that free 
copper only associates outside the targeted cells not uptake inside the cells, or is taken 





were very efficiently extracted into both cell lines. Thus, when compared to other 
tracers, 
64
CuCl2 showed lowest uptake. The uptake results of 
64
Cu-PTSM support the 
previous studies which suggest that it has potential as a tracer for labelling cells (101, 
103). Nonetheless, 
64
Cu (DEDTC)2 showed even greater influx into the cells, up to 
60% within 1 hr. Because slightly different uptake rate of the same tracer between two 
cells lines were observed uptake of radiotracer is somewhat cell type specific. Possibly 
cell size and surface area may account for this, or the rate of bioreduction of Cu(II) 
(which, followed by ligand dissociation, is believed to be the primary mechanism of 
intracellular trapping within the cell).  
However, experiments indicated a high degree of interaction between 
64
Cu 
(DEDTC)2 and plastic ware, up to 80% at 120 min after incubation. More importantly, 
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approximately 50% of attached activity on the plate can be detached by NaOH at the 
same time point. Therefore, the apparent percentage uptake of 
64
Cu (DEDTC)2 in the 
previous experiments were not only activity uptake by cells but also activity that had 
bound to the plate and was subsequently removed by washing. Therefore, the reaction 
between tracer and plastic containers should be investigated to validate the uptake 
results; based on these preliminary results, the rate of tracers extracted into the cells 
cannot be analysed accurately. Therefore we investigated the intracellular 
accumulation and the retention of the radiocopper tracers using glass tubes instead of 
plastic plates, with the cells in suspension. All of the radiotracers used in these 
experiments were also the subject of cell-free controls to determine the degree of 
binding to the reaction tubes. All of the radiocopper tracers showed negligible binding 
to the tube expect for 
64
Cu (DMDTC)2 and 
64
Cu (DPDTC)2 which bound to tubes to 
the extent of about 3% and 5%, respectively. For intracellular uptake and retention 
studies, because the same number of cells were seeded into the tubes on the day of 
experiment, leading to normalisation among the samples, the protein assay was 
unnecessary in these experiments. The cellular uptake of 
64
Cu BTSC complexes (PTS, 
PTSM, GTS and GTSM) in J774 cells showed time-dependent accumulation of the 
tracers. The highest uptake at 60 min was over 50% for all radiocopper BTSC 








Cu-PTSM. A similar pattern was also observed in eGFP-5T33 cells 






Cu-PTSM. The efficient 
and very rapid uptake of 
64
Cu-GTSM into both of cell types was expected owing to the 
relatively high reduction potential of this complex, which results in very rapid non-
selective bioreductive trapping in cells, as reported by Dearling and colleagues (107). 




Cu (DEDTC)2 and 
64
Cu (DPDTC)2 showed efficient 





Cu (DMDTC)2 was observed. However, the accumulated activity of 
64
Cu 
(DMDTC)2  in eGFP-5T33 cells was greater than 
 64
Cu (DEDTC)2 over the period of 
study. This finding suggests cell type dependence. 
When comparing the complexes of BTSCs and DTCs in eGFP-5T33 cells, 
although the influx of 
64
Cu (DTC) complexes were higher than that of 
64
Cu (BTSC) 
complexes in the cells, a plateau of uptake of 
64
Cu (BTSC) complexes was not clearly 




Cu-PTSM. Therefore longer incubation time 
might be considered. According to the study of Griessinger and colleagues, the 
optimum time to labelled murine Th1 cells with 
64
Cu-PTSM was up to 3 hr in order to 
reach the cell labelling efficiency between 6.5% - 9% (106). From another study, C6 
rat glioma cells, were incubated for 5 hr to achieve 70% - 85% cell uptake and it was 
necessary to take up 
64
Cu-PTSM for 90 min before performing subsequent efflux 
experiments (101). These combined observations suggest that longer incubation with 
64
Cu-PTSM (longer than 1 hr) might be necessary to achieve a higher labelling 
efficiency.  
Once radiolabelling efficiency and rates had been determined in 24 well plates, 
efflux of 
64




Cu (DEDTC)2 was 
performed (in 24 well plate) and compared in J774 and HCT 116 cells. 
64
Cu-PTSM 
was rapidly washed out from the labelled cells; up to 30-40% leakage occurred after 
incubation for 1 hr after the end of labelling in both cell types. At 24 hr, only 40% and 
50% of the activity remained in J774 and HCT 116 cells, respectively. The associated 
activity of 
64
Cu (DEDTC)2 in J774 and HCT 116 cells was around 30% and 70%, 
respectively, 24 hr after labelling. Based on the observation that 
64
Cu (DEDTC)2 was 
absorbed and leached from the multiwell plates, these retention results could be 
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affected by leaching activity from the multiwell plates which were used for the 
previous uptake experiments. 
In addition, therefore, the retention of activity of various 
64
Cu BTSC complexes 
and 
64
Cu DTC complexes in J774 cells were determined in glass test tubes. The results 
showed rapid wash out of the radio tracers from the labelled cells with less than 30% 
of initial activity remaining in the cells after incubation for 20 hr with all the 
64
Cu 
complexes. In the different cell type, eGFP-5T33 cells, the efflux of 
64
Cu BTSC 
complexes (PTS, PTSM and GTSM) and 
64
Cu (DEDTC)2 in the first four hours was 
significant with up to 60% released from the cells. Wash out of the lipophilic 
complexes of 
64
Cu either with BTSC or DTC ligands was remarkably similar in 
different cell types and different ligands. These finding are similar to previous studies 
from several groups which showed high efflux rate of lipophilic radiocopper complex 
in various types of cells (101, 106). This suggests that although different complexes 
lead to different rates and efficiencies of labelling, the efflux of 
64
Cu from cells is 
unrelated to the ligand. This is consistent with the hypothesis that dissociation of the 
complex is a common step in the intracellular trapping of the copper and that after this, 
efflux of copper by cellular homeostatic pathways specific to copper is likely to be 
responsible for removing copper from the cells. As previously described, copper 
generally binds to proteins (such as copper-dependent apoenzymes, ceruloplasmin and 
metallothionein) resulting in delivery of copper to the target molecules or proteins as 
well as keeping copper in the form of free ion to a minimum. This homeostasis might 
support the rapid wash out of radiocopper complexes from the labelled cells. However, 
the species of copper isotope that is dissociated from labelled cells has not been 
identified. Thus, it should be advantageous to identify the chemical form in which the 
radiotracer is exported. This knowledge would assist in the design of methods and 




The complexes of 
64
Cu (DEDTC)2 and 
64
Cu-PTSM were successfully synthesised by a 
method that proved to be simple, quick, reliable and reproducible. The amount of 
DEDTC ligand was optimised to achieve the radiolabelling efficiency with the lowest 




Cu (DEDTC)2 was characterised against its cold complex analogue 
using HPLC. Quality control of the complexes was performed by TLC. The results 
showed that the quality of 
64
Cu (DEDTC)2 and 
64
Cu PTSM are acceptable for further 
experiments. 
The procedures for time course of the uptake and efflux in this study were 
developed and validated. The most reliable method was to ensure that the same 
number of cells were freshly seeded before the experiments and carrying out the cell 
labelling in the test tube instead of in the plastic plate. This procedure can overcome 
the problem of the variation from the protein measurement and the differences of cell 
size as well as eliminating the problem of the tracers binding to the plastic reaction 
containers and multi-well plates.  
The 
64
Cu BTSC complexes, especially 
64
Cu-GTSM, were efficiently 
accumulated in various cell types. Similarly, 
64
Cu complexes of DTC showed very 
efficient extraction into the cells, especially 
64
Cu (DEDTC)2 which showed very rapid 
influx into the cells a few minutes after incubation. On the other hand, high efflux rate 
of radiocopper from cells labelled with either the 
64
Cu BTSC or 
64
Cu DTC complexes 
was observed, and the retained activities of 
64
Cu were lower than 30% at 24 hr post 
labelling for all of lipophilic radiocopper complexes. 
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Our results indicate that while the lipophilic 
64
Cu complexes of either BTSCs 
or DTCs are able to label cells remarkably quickly and efficiently, they lack the 
important property of prolonged retention in the labelled cells for a period compatible 
with the half life of the radionuclide. Therefore these complexes are not suitable 
radiotracers for direct labelling and tracking the labelled cells for a long period of time; 
indeed, it is possible that copper radionuclides in general are unsuitable as cell tracking 
agents for this reason. Further work is needed to identify suitable PET tracers for 




Chapter 3: Synthesis of lipophilic complexes of 
89
Zr and in 




In recent years, a non-standard long lived positron emitteing radionuclide, 
zirconium-89 has been increasingly available. 
89
Zr emits a positron in 23 % of its 
decays (maximum energy = 897 keV) and high energy gamma emission at 909 keV 
(99% abundance). Its physical half life is 78 hour (3.2 d) (134). Owing to 
89
Zr decay 
characteristics, it has been increasingly considered as a label for molecules which have 
slow pharmacokinetic clearance in the blood circulation such as antibodies, proteins or 
nanoparticles (135, 136). Desferrioxamine (DFO) has been widely used as a 
bifunctional chelator to form stable complexes between 
89
Zr and these molecules (137). 
Because of the long accumulation period to the targets (tissues or tumours) and slow 
clearance process of antibodies leading to  delays in achieving high target to 
background ratios (e.g. a few days), the long half life of 
89
Zr is useful for in vivo 
antibody imaging to allow sequential PET imaging and 
89
Zr has been mainly employed 
for immuno-PET. Although 
89
Zr properties are striking as a potential of cell labelling 
radioisotope (especially for application in cell based therapy), it has not been used for 
direct labelling of cells. It is therefore a challenge to label cells with zirconium-89 
complex for in vivo imaging and cell tracking. Its dominant oxidation number is 4+, 
compared to 3+ in the case of 
111
In. The ligands which can be complexed with 
111
In 
might also react with 
89
Zr in the similar manner. As both of them are radiometals, the 
mechanism to exploit cell labelling should be similarly applied using the lipophilic 
property of the radiocomplexes which are able to passively across cell membrane 
before dissociation of the complexes in the cells leading to released radiometals 
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becoming trapped by biomolecules inside the cells. Therefore the potential of lipophilic 
89
Zr radiotracers for cell labelling needs to be investigated.  
 
89
Zr can be produced by cyclotron bombardment via 2 nuclear reactions. The 
reaction mostly used to produce 
89




Zr reaction. The target, natural 
yttrium (
89
Y) is bombarded with a photon beam (energy 14-14.5 MeV) for 2-3 hr to get 
the product of 
89
Zr (138). Another reaction uses a 16 MeV deuteron beam to irradiate 




Zr (139). The 
89
Zr from both reactions 
is dissolved in hydrochloric acid HCl) and then 
89
Zr in the acid solution is separated 
from its starting material and purified by ion exchange chromatography (140). HCl is 
used to elute impurities while 
89
Zr is strongly bonded to the column. Then 
89
Zr is 
successfully transchelated from the column by oxalic acid (at least 0.5 M) (140). 
 In order to label cells with 
89
Zr radiotracer, it is proposed that zirconium-89 
should be considered in the form of a lipophilic complex, based on knowledge of 
mechanisms of other radiotracers (e.g. 
111
In-oxine) currently used to label cells. It is 
know that tetravalent zirconium can form complexes with monobasic bidentate ligands 
such as oxinate (141), tropolonate (142) and hydroxamates (143) of the stoichiometry 





In this section we aimed to synthesise a lipophilic complex of 
89
Zr with 8-
hydroxyquinoline (oxine). The production procedure (time and concentration of 
ligand) was investigated to determine the optimum conditions. We also aimed to 
evaluate the in vitro uptake and efflux of [89Zr]-Zr(oxinate)4 in different cell types 
including human white blood cells. In addition, labelling of multiple myeloma cells 
with [89Zr]-Zr(oxinate)4 was performed prior to in vivo imaging.  
 
3.3 Materials and Methods 
89
Zr used in the following studies was purchased from Perkin-Elmer (Seer 
Green, UK) in the form of 
89
Zr in 0.1 M oxalic acid. 8-hydroxyquinoline (oxine) from 
Sigma, USA was used. Radioactivity and count rate of radioactivity was measured and 
counted in a dose calibrator (Capintec CRC-25) and a gamma counter (Wallac 1282 
Compugamma Universal Gamma counter), respectively. Radiochromatograms of ITLC 
strips were scanned with a TLC scanner (LabLogic, UK) fitted with a β-/+ detector (B-
FC-3600) using Laura (v. 4.0.3.75) software (LabLogic, UK). 
Mouse macrophage cell line (J774), breast adenocarcinoma cell line (MDA-
MB-231) and murine multiple myeloma cell line (eGFP-5T33) were used for the in 
vitro experiments. Numbers of cells were counted with a cell counting machine 
(Countess automated cell counter, Invitrogen, USA). 
3.3.1 Synthesis of [89Zr]-Zr(oxinate)4 complex 
In order to synthesise [89Zr]-Zr(oxinate)4 complex, a  solvent extraction 
technique was applied using one-to-one (volume) ratio of chloroform and water 
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(organic phase and aqueous phase, respectively, vide infra). The lipophilic ligand was 




Zr oxalate) in the 
aqueous phase and then the lipophilic complex of [89Zr]-Zr(oxinate)4 dissolved in the 




Zr oxalate prepared from 1 volume of 
89
Zr in 0.1 
M oxalic acid neutralised with approximately 0.5 equivalent volume of 1 M sodium 
carbonate (Na2CO3) to pH 7. To find the best conditions (i.e. those resulting in the best 
radiolabelling yield), reaction time and amount (concentration) of ligand were varied as 
follows.  
3.3.1.1 Optimisation of the reaction time 
In this set of experiment, labelling efficiencies were assessed as a function of 
the reaction times (15 min, 45 min and 60 min) in duplicate for each time point. One to 
two MBq of 
89
Zr in 0.1 M oxalic acid was neutralised with approximately 0.5 
equivalent volume of 1 M sodium carbonate (Na2CO3) to pH 7 before adding water to 
bring the volume to 100 l as a stock solution. Ten l of neutralised 89Zr stock solution 
was dispensed into 15 ml Falcon tube then water was added to make the final volume 
to 500 l. Five hundred micrograms of 8-hydroxyquinoline (oxine) dissolved in 500 l 
chloroform were added to neutralised 
89
Zr in the tube. The mixture was continuously 
vortexed for 15 min, 45 min and 60 min then allowed to stand for 5 minutes to achieve 
complete separation of chloroform phase and water. 300 l of each phase were 
transferred into 1.5 ml microcentrifuge tubes separately. Radioactivities were counted 
by gamma counter (Wallac 1282 Compugamma Universal Gamma counter). The count 
rates (count per minute (cpm)) of the paired samples between two phases from their 
original reactions were calculated for labelling efficiency. The equation was defined as 
follows,   
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         Labelling efficiency = (CPMchlo * 100)/ (CPMchlo + CPMaq)  
         where                     CPMchlo = count rate in chloroform phase  
        CPMaq = count rate in aqueous (water) phase 
3.3.1.2 Optimisation amount of oxine 
In this experiment we sought to determine the lowest amount of oxine which 
can be used to achieve acceptable labelling efficiency (N.B. oxine is cytotoxic (144). 
Oxine quantities of 100 g, 300 g and 500 g (1.4 mmol, 4.2 mmol and 7.0 mmol, 
respectively) were used to synthesise [89Zr]-Zr(oxinate)4. The procedures to synthesise 
89
Zr complex were the same as described above with mixing time kept at 15 min for 
every reaction. The mixture was allowed to fully separate for 3 min. Subsequently, 2 l 
of the chloroform phase were used to determine the labelling efficiency using solvent 
extraction which was the mixture between 0.5 ml of PBS and 0.5 ml chloroform to be 
used. Reactions were mixed with a vortexer for 5 min and left to separate for 3 min 
then 100 l of each phase was collected into new 1.5 ml microcentrifuge tubes 
separately. Radioactivity in the PBS phase and chloroform phase was measured in the 
gamma counter. At the end, radiolabelling efficiencies were determined using the same 
equation as shown previously in the section 3.3.1.1 on time optimisation. 
3.3.1.3 Synthesis of [89Zr]-Zr(oxinate)4 complex for in vitro biological evaluation 
For the following experiments to label cells for in vitro studies, [89Zr]-
Zr(oxinate)4 was synthesised using the following (optimised) protocols. Five to ten 
MBq of neutralised 
89
Zr (pH 7) was prepared as described in section 3.3.1.1 and diluted 
to a final volume of 500 l with distilled water. A 5 ml heart shaped glass flask was 
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used instead of Falcon tubes to avoid losses due to adsorption reactions between 
organic solvent and plastic material. Five hundred g of oxine in 500 l of chloroform 
were added to neutralised 
89
Zr in the glass flask. The mixture was continuously 
vortexed for 15 min prior to transferring the contents to 1 ml glass vial with a v-shaped 
bottom using a glass pasteur pipette. The two solution phases were left to separate 
completely (ca. 5 min) then the chloroform phase containing [89Zr]-Zr(oxinate)4 was 
collected and transferred into a new small glass vial. Chloroform was completely 
evaporated by heating at around 60
o
C using a heating block. The residue complex was 
redissolved in 10-20 l of DMSO to obtain [89Zr]-Zr(oxinate)4. In order to use [89Zr]-
Zr(oxinate)4 the DMSO was diluted with serum free medium or normal saline for use in 
uptake and efflux studies with myeloma cells and white blood cells. 
[89Zr]-Zr(oxinate)4 used for in vivo studies was synthesised in the same 
procedures as for in vitro study but the starting activity of 
89
Zr was increased to around 
45 MBq or more in order to obtain enough activity for PET imaging. After the first run 
of synthesising [89Zr]-Zr(oxinate)4 in which [89Zr]-Zr(oxinate)4 in chloroform phase was 
completely removed from the V-shape bottom glass vial, the remaining aqueous phase 
containing unreacted neutralised 
89
Zr solution was reused in further extractions of 
[89Zr]-Zr(oxinate)4 by transferring to 5 ml reaction glass flask, adding 500 l of 1 
mg/ml oxine in chloroform and repeating all the procedures for synthesising [89Zr]-
Zr(oxinate)4. Activities of initial neutralised 
89
Zr and [89Zr]-Zr(oxinate)4 were measured 
with a dose calibrator. Labelling efficiencies were calculated using equation as follows: 
Labelling efficiency = (Act
89
Zr oxine * 100) / Actint 
where              Act
89
Zr oxine  = Activity of produced [
89Zr]-Zr(oxinate)4 





However, to determine labelling efficiency, only the first synthesising 
extraction can be precisely calculated because activities of subsequently reuse 
89
Zr 
solutions were not actually measured. Those activities could be estimated as follows. 
The initial activity of neutralised 
89
Zr in each synthesis which was measured with the 
dose calibrator was subtracted with the activity of produced [89Zr]-Zr(oxinate)4 in the 
correspondent extraction. The rest of the activity became the initial activity of the 
subsequent extraction. Then calculations were repeated in the same manner for the 
following production and applied to all of 5 syntheses.   
3.3.2 Quality control of [89Zr]-Zr(oxinate)4 
In this study two techniques were used to determine radiochemical purity of 
[89Zr]-Zr(oxinate)4 complex, instant thin layer chromatography (ITLC) and solvent 
extraction. For ITLC, instant thin layer chromatography strips impregnated with silica 
gel (ITLC-SG) were cut into 1 cm X 8 cm strips, the origin and solvent front were 
marked with pencil at 1 cm and 7.5 cm, respectively, from the edge of strip. In order to 
verify the Rf of [89Zr]-Zr(oxinate)4 in thin layer chromatography system, cold zirconium 
oxine complex Zr(oxinate)4 of verified formula and purity was provided from Mr. 
Trevor J Ferris, School of Physical Sciences, University of Kent, UK. A small amount 
of Zr(oxinate)4 (yellow powder) was dissolved in DMSO. Then 1 l of this solution 
was spotted on ITLC-SG strip. The separation was developed in mobile phase, ethyl 
acetate, until the solvent reached the solvent front line. The zirconium complex was 
visualised and marked in UV box with a short wavelength. The Rf of neutralised 
89
Zr 
was determined in the same system. Using this method [89Zr]-Zr(oxinate)4 dissolved in 
DMSO prior to dilution with saline was verified against with cold complex and 
compared with neutralized 
89
Zr. Radiochromatograms were scanned with a TLC 
scanner (LabLogic, UK) using Laura (v. 4.0.3.75) software (LabLogic, UK). 
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For solvent extraction technique, the two-phase system was prepared prior to 
the experiment. A one to one volume by volume (50 ml for each phase) mixture of PBS 
and chloroform was mixed and left to equilibrate for around 2-3 hours before using.  
Preferential solubility of free 
89
Zr and [89Zr]-Zr(oxinate)4 between two phases was 
determined so that we could calculate percentage of labelling yield in any following 
samples. 0.5 ml of each phase was transferred into 15 ml Falcon tubes. 0.5 l of 
neutralised 
89
Zr or [89Zr]-Zr(oxinate)4 (dissolved in DMSO) was added into this mixture 
then it was continuously vortexed for 1 minute and left to stand for 3 min. One hundred 
l of each phase were transferred to 1.5 ml eppendorff tubes and count rate (count per 
minute) was measured in the gamma counter. Then to calculate radiochemical purity of 
[89Zr]-Zr(oxinate)4 complex, count rate of 89Zr in the organic phase was divided by total 
count rate in both phases and multiply by one hundred as shown in equation below.  
Radiochemical purity = (CPM organic phase) * 100/ (CPM organic phase + CPM aqueous phase)  
3.3.3 Cell culture 
 Mouse macrophages (J774), breast adenocarcinoma cells (MDA-MB-231) and 
mouse myeloma eGFP-5T33 were used to investigate the rate and percentage of uptake 
and efflux of [89Zr]-Zr(oxinate)4. J774 cell line was kindly provided by Dr. Helen 
Collins, Department of Infectious Diseases, King‟s College London. Cells were 
cultured in adhesion semi-continuous culture in high glucose (4.5 g/l glucose) DMEM 
supplemented with 10% foetal bovine serum, 2 mM L-glutamine, 
penicillin/streptomycin (5 ml of 5000U pen/ 5000 g/ml strep), 1 mM sodium pyruvate 
and 10 mM HEPES. MDA-MB-231 cell line was provided from University of 
Manchester (ATCC-HTB-26). MDA-MB-231 were semi-continuously grown as 
adhesion culture in medium containing 10% fetal bovine serum, 2mM L-glutamine and 
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25000 U penicillin/25 mg streptomycin. All cell lines were cultured under a humidified 
atmosphere at 37
o
C with 5% CO2.  
On the experiment day, culture medium of J774 cells was removed and the J774 
adhesion cells were washed twice with PBS (10 ml and 20 ml in 75 cm
2
 and 175 cm
2
 
flask, respectively). Serum-free medium was added and cells were scraped from the 
culture flask and gently mixed before counting. For MDA-MB-231 cells, after 
removing culture medium and washing the cells with PBS, trypsin (1 ml and 2 ml for 
75 cm
2
 and 175 cm
2
 culture flask, respectively) was added into pre-washed cells and 
further incubated in 37
o
C incubator for 5 min to detach cells from the flask. Medium 
was added to stop the reaction and cells were counted in a cell counting machine 
(Countess automated cell counter, Invitrogen, USA). Both cell types were diluted to a 
final concentration of 1x10
6
 cells in 450 l of serum free medium then dispensed into 
glass test tubes for labelling experiments. 
 The eGFP-5T33 murine multiple myeloma cell line was provided by Dr 
Yolanda Calle (University of Roehampton) and used for in vitro studies and in vivo cell 
tracking. Cells were grown in suspension culture in RPMI 1640 supplemented with 
10% foetal bovine serum, L-glutamine and penicillin/streptomycin semi-continuously 
in humidified 37
o
C with 5% CO2. Cells were subcultured by transferring the cell 
suspension to a new 50 ml falcon tube followed by centrifugation at 2000 RPM for 5 
min. The supernatant was discarded and the cell pellet was resuspended in fresh culture 
medium and transferred to new culture flask. In order to prepare cells for particular 
experiments, the cell pellet was washed with PBS twice before counting cell numbers 




3.3.4 Uptake and efflux experiments 
 In order to investigate in vitro uptake of tracer, [89Zr]-Zr(oxinate)4  and 
neutralized 
89
Zr were diluted to 0.05 MBq per 50 l serum free medium before adding 
to each glass reaction tube containing with 1x10
6
 cells (J774, MDA-MB-231 or eGFP-
5T33) in 450 l serum free medium. The percentages of 89Zr tracer taken up by all 
three cell types were determined at 5 time points (1, 15, 30, 45 and 60 min) during 
incubation at room temperature. At each point, the reaction tubes were centrifuged at 
2000 RPM for 5 min. Four hundred and fifty microlitres of supernatant were 
transferred into a new tube. Cell pellets (including residual supernatant) and their 
corresponding supernatants were counted in gamma counter to calculate the percentage 
of radioactivity in labelled cells in each time point. The percentage of radiotracers 
taken up in the cells was calculated as shown in the equation as follows: 
 % uptake in the cells  =  (CPM act cell*100)/ (CPM cell + CPM sup) 
    CPM act cell   =  CPM cell – ((CPM sup * 50)/450) 
where    CPM act cell  =  actual count rate of the cell pellet corrected with the 
count rate of 50 ml residual of supernatant  
      CPM cell    =   count rate of the cell pellet 
      CPM sup    =   count rate of the supernatant 
The experiments were repeated 3 times. [
111
In]-In(oxinate)3 was also used as a 
radiolabel, for comparison, using similar procedures, in the case of the J774 cell line. 
0.1 MBq of [
111
In]-In(oxinate)3 (GE Healthcare, UK) was added per cell sample and 
then the experiments were performed as described for zirconium tracers. In addition, 
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cell free controls were analysed in the same way at the same time points to determine 
degree of binding of tracers to the glass reaction tubes.  
 For the efflux study, cells were incubated with the tracer for 30 min using the 
same conditions as in the uptake study described above. After removing the 
supernatant, cell pellets were washed with 500 l of PBS twice to remove excess 
radiotracer. Five hundred microlitres of fresh medium supplemented with 10% FBS 
were added into each tube. Tracer retention was determined at 1, 2, 3, 20 and 24 hr post 
labelling for J774 and MDA-MB-231 cells with [89Zr]-Zr(oxinate)4 and [
111
In]-
In(oxinate)3 whereas the retention of eGFP-5T33 cells with [
89Zr]-Zr(oxinate)4 was 
determined at 1, 20 and 24 hr after labelling. At each time point, samples were 
centrifuged at 2000 RPM for 5 min to pellet the cells. Five hundred microlitres of 
supernatant were removed to a new tube. Radioactivity in the cell pellets and 
corresponding supernatants were counted in gamma counter. Percentage retention of 
tracers in the labelled cells was calculated from activity in the cell pellets compared to 
total activity in cells and supernatants.  
3.3.5 Labelling the eGFP-5T33 myeloma cell line 
The 5T33 is a syngeneic murine multiple myeloma model that originates from 
the C57Bl/KaLwRij (immunocompetent) strain. Cells can be maintained in vitro and 
disease can be induced by i.v. inoculation. The model has been used for 3 years in our 
laboratories, and based on our previous experience (in which cell tracking with In-111 
had been used to characterise the model) we decided to evaluate the radiotracer in this 
model for comparison. Therefore, before in vivo study was performed, the percentage 
of [89Zr]-Zr(oxinate)4 taken up by eGFP-5T33 cells was determined. Because [
111
In]-
In(oxinate)3 is one of the standard radiopharmaceuticals for labelling white blood cells 





In(oxinate)3 to compare with [
89Zr]-Zr(oxinate)4. Since for in vivo imaging of labelled 
cells a higher activity of labelled cells is needed compared with in vitro uptake studies, 
higher activities of [89Zr]-Zr(oxinate)4 and [
111
In]-In(oxinate)3 were used. In this 





In]-In(oxinate)3, as follows.  
Twenty microlitres of eGFP-5T33 cells suspension was dispensed from the 
culture flask to count cells using automated cell counter. Approximately 10
7 
cells were 
transferred from the culture flask into a 50 ml falcon tube and centrifuged at 2000 RPM 
for 5 min. The supernatant was discarded and the cell pellet was washed twice with 15 
ml PBS.  After washing, cell pellets were resuspended in serum-free medium and cell 
concentration and viability was determined in the Invitrogen cell counter based on 
trypan blue exclusion. The cell suspension was diluted to a final cell concentration of 
4.0 x 10
6
 to 7.5 x 10
6
 cells per ml. Then 7.5 x 10
6
- 1.5 x 10
7
 eGFP-5T33 cells were 
transferred to 50 ml Falcon tube and then serum-free medium was added to reach a 







were diluted to 1 ml in serum-free cell culture medium. For neutralised 
89
Zr, activity 




89Zr]-Zr(oxinate)4 were performed both with higher (7 and 5 MBq) 
and lower (2 and 0.3 MBq) activities. Diluted radiotracers were added dropwise to the 
cell suspensions in the 50 ml Falcon tubes. Actual added activities in the tubes were 
measured in dose calibrator. The suspensions were incubated at room temperature for 
30 min and gently shaken occasionally. After incubation, 7 ml of PBS were added and 
then centrifuged at 2000 RPM for 5 min. The supernatant (SN) was removed and cell 




 wash). Supernatants and 
100 
 
washing solutions in every step were collected in the same tube; the radioactivities of 
supernatants were measured in the dose calibrator prior to pooling washing solutions. 
After the second washing step, cell pellets were resuspended in 12-15 ml of cell culture 
medium then activities in the labelled cells were measured. Cell viabilities and 
concentrations were measured in the Invitrogen cell counter using trypan blue 
exclusion. 
3.3.6 Labelling human white blood cells with [89Zr]-Zr(oxinate)4 
The routine clinical procedure developed for white blood cell labelling at the 
Department of Nuclear Medicine, Guy‟s Hospital, was followed in this study (details 
below). Human WBCs were labelled with [89Zr]-Zr(oxinate)4 instead of [
111
In]-
In(oxinate)3 or Tc-99m HMPAO which were commercial available and widely used in 
Nuclear Medicine using similar SOPs for radiolabelling white blood cells.  
[89Zr]-Zr(oxinate)4 was synthesised from 
89
Zr oxalate and oxine as described 
previously. After chloroform was completely evaporated from the organic phase of 
[89Zr]-Zr(oxinate)4 solution, residual [89Zr]-Zr(oxinate)4 was redissolved in 15 l of 
DMSO then transferred to a small glass vial. QC of tracer was performed as described 
above (i.e. solvent extraction in PBS and chloroform mixture and ITLC). 
Radiochemical purity of the tracer was higher than 95%. Activity of [89Zr]-Zr(oxinate)4 
in DMSO was measured in the dose calibrator.  
The syringe for blood collection was prepared as follows. A fifty ml syringe 
containing 500 U of heparin (heparin 1000 units/ml in ampoule), was prepared. A 20 
gauge scalp-vein cannula (chosen because the extension cannula in its set offers more 
efficient and flexible handling and reduced risk of dislodging when drawing high 
volume of blood from peripheral vein) was attached to the heparinised syringe and 55 
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ml blood was withdrawn from a peripheral vein of a volunteer, slowly to avoid red 
blood cell haemolysis. The cannula was replaced on the syringe by a red luer lock 
syringe cap. The syringe was gently inverted 4-5 times to complete mixing of blood 
with heparin. The blood filled syringe was carefully handled and wiped with 70% IMS 
to avoid contamination from blood infection. 
The entire WBCs labelling procedure was performed inside a laminar flow 
cabinet as follows. Two ml of Methocel 2% (to help red blood cells to sediment from 
white blood cells efficiently) were added into a 50 ml Falcon tube. 45 ml of the 
anticoagulant-blood mixture were transferred into the prepared 50 ml Falcon tube 
labelled as sample A. The tube was sealed then contents were mixed very gently. The 
remaining 10 ml of the anticoagulant blood mixture were transferred to a new 15 ml 
Falcon tube labelled as sample B. Both tubes were placed upright in a plastic rack. To 
separate white blood cells for subsequent labelling with the radiotracer, the 50 ml 
Falcon tube, sample A, was centrifuged at 210 RPM for 15 min. After centrifugation, 
the upper layer (supernatant) contained white blood cells, platelets and leukocyte rich 
plasma (LRP). A 20 ml syringe attached to kwill tube (a plastic cannula used instead of 
a needle, to reduce damage to cells) was used to withdraw the supernatant without 
disturbing the packed red blood cell layer. The supernatant was transferred into a new 
50 ml Falcon tube then centrifuged at 900 RPM for 5 min. After centrifugation, white 
blood cells formed a pellet at the bottom of the tube, and the supernatant layer was 
platelet-rich plasma (PRP). The supernatant was gently removed to avoid disturbing 
packed of white blood cells by using syringe attached to a kwill. The pellet was then 
washed in 10 ml of isotonic saline (sodium chloride 0.9% w/v) to remove plasma 
residues. The tube was centrifuged at 900 RPM for 5 min then the supernatant was 
discarded. The pellet was gently resuspended in 1 ml of saline then transferred into a 
glass test tube. [89Zr]-Zr(oxinate)4 in 15 l DMSO was diluted with 1 ml normal saline 
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then added to the above cell suspension and mixed very gently. The tracer was 
incubated with white blood cells at room temperature for 15 min. In the meantime 
platelet-poor plasma (PPP) was prepared from sample B by centrifuging the sample at 
2000 RPM for 5 min. The supernatant layer consisting of PPP was collected in a new 
15 ml Falcon tube. This solution was kept and used to dilute and resuspend WBCs 
after labelling with radiotracer to simulate physiological conditions. After incubating 
WBCs with [89Zr]-Zr(oxinate)4 for 15 min, the cell suspension containing the labelled 
cells was withdrawn with auto-pipette and transferred back to the original 50 ml 
Falcon tube. Three ml of PPP were added to radioactive white blood cell suspension 
and saline was used to dilute the solution to 10 ml. The mixture was then centrifuged at 
900 RPM for 5 min. Then supernatant containing unbound [89Zr]-Zr(oxinate)4 was 
carefully withdrawn without disturbing the white cell pellet and collected into a new 
50 ml Falcon tube. The radiolabelled white blood cell pellet was gently re-suspended 
in 3 ml of PPP. Activities in the labelled cells and supernatant were measured in the 
dose calibrator. Cell labelling yield was calculated as activity in the labelled white 
cells divided by the sum of activity in the labelled cells and supernatant then multiplied 
by one hundred shown in the equation as follows.  
Cell labelling yield = (Act cell) * 100 / (Act cell + Act sup) 
       where              Act cell = Activity of the labelled white blood cells 
                        Act sup = Activity of the supernatant 
The cells suspension was incubated in a tissue culture incubator (37
o
C, 95% 
air/5% CO2 humidified atmosphere). Retention of radioactivity was determined at 24 
hours after labelling. At the time point, the tube was taken from the incubator and 
processed as follows. Cells suspensions were centrifuged at 2000 RPM for 5 min. The 
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supernatant was carefully collected and transferred to another glass tube. Activities in 
labelled WBCs and in supernatant were measured and percentage of activity in the 
cells calculated.  
 
3.4 Results 
3.4.1 Optimisation of reaction time for [89Zr]-Zr(oxinate)4 synthesis (low activity) 
To determine the optimal reaction time to synthesise [89Zr]-Zr(oxinate)4, 1 - 2 
MBq neutralised 
89
Zr (aqueous phase) was incubated and agitated with 500 g oxine 
(chloroform phase) for 15, 45 and 60 min. (Upon separation the two phases were 
collected separately, [89Zr]-Zr(oxinate)4 and free 
89
Zr  in chloroform phase and aqueous 
phase, respectively, were collected and counted to determine the labelling efficiency.) 
Labelling efficiency was above 95% at each time point (results shown in Table 3.1). 
 
Time ( min) Labelling yield (%) 
15 95.3 ± 1.3  
45 97.0 ± 0.4 
60 95.5 ± 0.4 
 
Table 3.1: Labelling yield of [89Zr]-Zr(oxinate)4 with 500 g of oxine using solvent 





3.4.2 Optimisation of amount of oxine (low activity) 
After synthesising [89Zr]-Zr(oxinate)4 in presence of various amount of oxine 
ligand (using a 15 minute reaction time based on results above), radiolabelling 
efficiencies were determined, results are shown in Table 3.2. 
 
Amount of oxine (g) Labelling yield (%) 
100 81.7 ± 2.5 
300 92.4 ± 8.9 
500 96.9 ± 2.1 
 
Table 3.2: Labelling yield of [89Zr]-Zr(oxinate)4 with varied amount of oxine (n=4, 
3 and 4, respectively) 
3.4.3 Quality control of [89Zr]-Zr(oxinate)4 complex 
Chromatography of cold zirconium oxine was performed with ITLC-SG with 
ethyl acetate mobile phase, and showed the Rf of zirconium complex to be 0.9, 
detected under short wavelength UV. 
After synthesis of [89Zr]-Zr(oxinate)4 dissolved in DMSO, the radiochemical 
purity of [89Zr]-Zr(oxinate)4 was determined by using ITLC-SG with ethyl acetate 




Zr oxalate) was also analysed in the same system. Rf 
values of 
89
Zr oxalate and [89Zr]-Zr(oxinate)4 were 0 and 0.9, respectively, as shown in 






            
                                                                (A)      
                           
 
                                                                 ( B ) 
Figure 3.1: Radiochromatograms of 
89
Zr oxalate (A, Rf = 0) and [89Zr]-
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Solvent extraction results showed that 
89Zr oxalate (“free 89Zr”) was extracted 
in the aqueous phase whereas [89Zr]-Zr(oxinate)4 was dissolved in the chloroform 
phase. Radiochemical purity of [89Zr]-Zr(oxinate)4 (dissolved in DMSO) used 
subsequently for cell labelling was over 95%. 
3.4.4 Labelling efficiency of synthesis of [89Zr]-Zr(oxinate)4 for in vivo studies (high 
activity) 
Results of 5 syntheses of [89Zr]-Zr(oxinate)4 by the solvent extraction technique 
are summarised in Table 3.3. Radiochemical yields were much lower than with the low 













efficiency ( % )  
 
47.5 
1st 3.7 7.79  
 
 
2nd 23.1 52.74  
 
77.6 
1st 0.7 0.90  
 
 
2nd 5.5 7.15  
 
 
3rd 12.7 17.79  
 
 
4th 27.8 47.36 
 
50.7 
1st 10.0 19.70 
 
 
2nd 17.5 43.00 
 
 
3rd 9.0 38.79 
 
66.0 
1st 1.7 2.58 
 
 
2nd 24.8 38.57 
 
 















efficiency ( % )  
 
84.0 
1st 22.3 26.55 
 
 
2nd 23.2 37.60 
 
 
3rd 16.8 43.64 
 
 
4th 12.5 57.60 
 
 
5th 8.0 86.96 
   
Table 3.3: Results of five independent attempts to synthesise [89Zr]-Zr(oxinate)4 
for in vivo imaging using solvent extraction technique. “Starting activity” is the 
activity (i.e. activity added to the first 500 g of oxine) of neutralised 89Zr which was 
used to synthesise the first extraction of [89Zr]-Zr(oxinate)4. The first extraction of 
[89Zr]-Zr(oxinate)4 in chloroform phase was then separated. The activity of the 
chloroform phase (i.e. [89Zr]-Zr(oxinate)4) was measured as shown in the column of 
activity of [89Zr]-Zr(oxinate)4 (refer to Table 3.3) prior to evaporating chloroform 
before using for in vivo studies. Neutralised 
89
Zr was transferred to the glass flask and 
reused. A fresh 500 g of oxine in 500 l chloroform was added and the procedures 
for extracting were repeated to produce the subsequent extractions of [89Zr]-
Zr(oxinate)4 as shown in the sequence of synthesis for the second, third, fourth and 
fifth sequences (refer to Table 3.3). The starting activity in each extraction was the left 
over activity of 
89
Zr from the previous sequence (i.e. the aqueous phase was re-used 
with a new aliquot of oxine in chloroform).  
3.4.5 In vitro uptake and efflux of [89Zr]-Zr(oxinate)4 in cell lines 
[89Zr]-Zr(oxinate)4 uptake studies were carried out in J774 and MDA-MB-231 
cell lines. Neutralised 
89
Zr was used as a control. The accumulation of [89Zr]-
108 
 
Zr(oxinate)4 in both cell lines increased with time over an incubation period of 60 min 
(refer to Figure 3.2 and 3.3). The percentage of tracer uptake was similar in both cell 
lines. Neutralised 
89
Zr (in the form of 
89
Zr oxalate) exhibited relatively low uptake in 
both cell lines. The highest percentage of uptake of [89Zr]-Zr(oxinate)4 in J774 and 
MDA-MB-231 cells after 60 min of incubation was 23% and 20%, respectively, as 
shown in Figure 3.2 and 3.3. A slight uptake of neutralised 
89
Zr was observed in both 
cell lines however this was significantly lower than that of [89Zr]-Zr(oxinate)4 (Figure 
3.2 and 3.3). The uptake of [89Zr]-Zr(oxinate)4 was also determined in eGFP-5T33 
multiple myeloma cells. Results show that for 1 x 10
6
 cells, around 10% of the 
radiotracer was taken up after 60 minutes as shown in Figure 3.4. Meanwhile cellular 
uptake of [
111
In]-In(oxinate)3 was determined in J774 cells, the result was shown in 





Figure 3.2: Comparison of uptake of [89Zr]-Zr(oxinate)4 and neutralised 
89
Zr in 






















Figure 3.3: Comparison of [89Zr]-Zr(oxinate)4 and free 
89





Figure 3.4: Graph showing cellular uptake of [89Zr]-Zr(oxinate)4 in multiple 






































Figure 3.5: Graph showing cellular uptake of [
111
In]-In(oxinate)3 in mouse 
macrophages cells, J774, over 60 min. 
We also determined the extent of non-specific binding of [89Zr]-Zr(oxinate)4 to 
the glass reaction tubes. Results shown in Table 3.4 suggest that this was negligible.





binding to glass tube 
 
1 






0.24 ± 0.14 
 
45 
0.25 ± 0.11 
 
60 
0.29 ± 0.09 
         
Table 3.4: Degree of binding between [89Zr]-Zr(oxinate)4 and glass tube. The 
activity bound to glass tube was carried out in cell-free reaction in the same manner as 


















Examination of the efflux kinetics of [89Zr]-Zr(oxinate)4 in labelled cells 
showed that in J774 and MDA-MB-231 cell lines wash out from labelled cells was 
minimal: around 94% to 96% of tracer was retained in labelled cells in first 3 hours 
after labelling and around 91% and 82% was still associated with the J774 and MDA-
MB-231 cells, respectively, after 24 hours (Figure 3.6). [89Zr]-Zr(oxinate)4 in eGFP-
5T33 showed greater than 70% retention within the cells after 1 day post-labelling 
(Figure 3.7). [
111
In]-In(oxinate)3 was also examined to determine the percentage of 
retention in the labelled J774 and MDA-MB-231 cells; activity between 89% and 52% 
remained associated with J774 cells from 1 hr to 24 hr post labelling and similarly, 
90% to 44% activity was retained in the MDA-MB-231 cells at 1 hr and 24 hr post-




Figure 3.6: Percentage of 89Zr retained over a period of 24 hr in 1 x 10
6
 J774 cells 


































Figure 3.7: Graph shows the efflux of 89Zr from labelled eGFP-5T33 cells over 24 
hr post labelling. 
 
 
Figure 3.8: Percentage of 
111
In retained over a period of 24 hr in 1 x 10
6
 labelled 





















































3.4.6 Results of radiolabelling eGFP-5T33 cells 
Labelling with [89Zr]-Zr(oxinate)4 and [
111
In]-In(oxinate)3 were studied and 
compared in the eGFP-5T33 cell line.  Results are shown in Tables 3.5-3.7.  
 
 Tube 1 Tube 2 Tube 3 Tube 4 
Number of cells 7.5 x 10
6
  7.5 x 10
6
  7.5 x 10
6
  7.5 x 10
6
  





1.8 MBq 1.7 MBq 1.9 MBq 1.9 MBq 





 wash  
1.8 MBq 1.6 MBq 1.9 MBq 1.83 MBq 
Activity of cell pellet 0.1 MBq 0.1 MBq 0.1 MBq 0.1 MBq 
Viabilitya 75% 75% 75% 75% 




  5 x 10
6
  5 x 10
6
  5 x 10
6
  
Labelling yield 0% 5.0% 0% 3.68% 
 
Table 3.5: Neutralised 
89
Zr-oxalate labelling of eGFP-5T33 cells. Tubes 1-4 
represent labelling with neutralised 
89
Zr with eGFP-5T33 cells in four replicates. 
“Number of cells” refers to the initial number of cells used in the labelling procedure 
and number of labelled cells refers to the total number of cells after labelling. Viabilityi 
is the initial cell viability before starting the labelling process and viabilitya is the cell 
viability after the labelling procedure had been completed. Activity of SN is the activity 










 washing steps. Activity of cell pellet is the final activity of labelled cells. Labelling 
yield was calculated as the ratio of „activity of cell pellet‟ and added activity of tracer 
(neutralised 
89






 In several columns in Tables 3.5-3.7, the sum of activity of cell pellet, activity 
of supernatant and activity from washing steps is higher than the activity added to the 
tube. These (minor) differences can be accounted for by an instrument error (low 
accuracy of dose calibrator when measuring low activities). Cell labelling yield 
therefore was calculated based on the added activity and activity in supernatant 
including activity in washing buffer. Based on these calculations the uptake of 
neutralised 
89
Zr was very low.  
 
 Tube 1 Tube 2 Tube 3 Tube 4 
Number of cells 8.5 x 10
6
  8.5 x 10
6
  8.5 x 10
6
  8.5 x 10
6
  
Viabilityi 97% 97% 97% 97% 
89
Zr oxine added 5.50 MBq 0.33 MBq 0.30 MBq 0.30 MBq 
Activity of SN  2.47 MBq 0.2 MBq 0.2 MBq 0.2 MBq 




3.62 MBq 0.2 MBq 0.2 MBq 0.2 MBq 





 wash  
3.68 MBq 0.2 MBq 0.3 MBq 0.2 MBq 
Activity of cell pellet 1.6 MBq 0.1 MBq 0.1 MBq 0.1 MBq 
Viabilitya 70% 70% 70% 70% 




  6 x 10
6
  6 x 10
6
  6 x 10
6
  
Labelling yield 29.09% 30.00% 33.00% 33.00% 
 
Table 3.6: Results of [89Zr]-Zr(oxinate)4 labelling with eGFP-5T33 cells. In tube 1 
and tube 2-4, eGFP-5T33 cells were labelled with high and low activities of [89Zr]-






 Uptake of [89Zr]-Zr(oxinate)4 was between 29-33%; the percentage uptake was 
not affected by the activity (Table 3.6 and 3.7) (which is higher than that of neutralised 
89
Zr). Measurements of low activity also shows inaccuracy as in the previous 
experiment. 
 
 Tube 1 Tube 2 Tube 3 Tube 4 
Number of cells 1.3 x 10
7
  1.3 x 10
7
  1.3 x 10
7
  1.3 x 10
7
  
Viabilityi 97% 97% 97% 97% 
111
In oxine added 7.10 MBq 2.32 MBq 2.36 MBq 2.37 MBq 
Activity of SN  0.40 MBq 0.3 MBq 0.4 MBq 0.4 MBq 




0.50 MBq 0.4 MBq 0.4 MBq 0.5 MBq 





 wash  
0.7 MBq 0.4 MBq 0.4 MBq 0.6 MBq 
Activity of cell pellet 5.95 MBq 1.78 MBq 1.84 MBq 1.72 MBq 
Viabilitya 80% 80% 80% 80% 




  8.5 x 10
6
  8.5 x 10
6
  8.5 x 10
6
  
Labelling yield 83.80% 76.72% 77.97% 72.57% 
 
Table 3.7: Labelling of eGFP-5T33 cells with [
111
In]-In(oxinate)3. In tube 1 and 
tube 2-4, eGFP-5T33 cells were labelled with high and low activities of [
111
In]-
In(oxinate)3, respectively.  
 When labelling eGFP-5T33 cells with [
111
In]-In(oxinate)3, a greater percentage 
of tracer was taken up by the cells (up to about 84%) when compared to cells labelled 
with [89Zr]-Zr(oxinate)4.  
3.4.7 Results of human white blood cells labelled [89Zr]-Zr(oxinate)4 
 Human leukocytes were separated according to SOPs for [
111
In]-In(oxinate)3 
labelling white blood cells. Labelling yields in 3 independent experiments are 
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summarised in Table 3.8 for [89Zr]-Zr(oxinate)4 labelling and in Table 3.9 for the 
percentage of retention activity in the cells at 24 hr after labelling is shown. In the 
second efflux experiment of labelled white blood cells, due to low activity the 





















 11.10 1.8 9.10 10.90 16.50 
2
nd
 3.05 0.5 2.33 2.83 17.67 
3
rd
 16.20 2.5 13.55 16.05 15.58 
 




labelled WBCs @ 
24 hr (MBq) 
Activity in 
supernatant @ 24 
h (MBq) 
% retention activity 
in labelled WBCs    
@ 24 hr 
1
st
 1.15 0.20 85.19 
3
rd
 1.65 0.25 86.85 
 
Table 3.9: Retained activity of [89Zr]-Zr(oxinate)4 in human white blood cells 24 









 In order to synthesise [89Zr]-Zr(oxinate)4 complex, a solvent extraction 
technique was used. The problem of low labelling yield when plastic containers were 
used in the synthesis process might be due to reaction of organic solvent with plastic 
containers leading to contamination by the eluted impurity in the reaction (data not 
shown). To overcome the problem, glass devices and glass containers were chosen in 
the synthesis process especially for [89Zr]-Zr(oxinate)4 which was further investigated 
in both in vitro and in vivo experiments.    
The results from optimisation of time of synthesis of [89Zr]-Zr(oxinate)4 with 
low activities of 89Zr showed that a reaction time of only 15 min was sufficient to 
produce [89Zr]-Zr(oxinate)4 with labelling efficiency greater than 95%. Results of 
experiments to determine the effect of varying the quantity of oxine indicated that 
labelling yield was correlated to the amount of oxine. Using 500 g of oxine showed 
the highest labelling yield, around 97% compared to 300 g and 100 g (about 92% 
and 82%, respectively). The optimal conditions therefore selected were 500 g of 
oxine with incubation for 15 min. Under these condition, with low activities of 
89
Zr 
(i.e. low volumes of the supplied 
89
Zr in oxalic acid) the radiochemical yield is 
excellent. Therefore in the following experiments, a protocol to synthesise [89Zr]-
Zr(oxinate)4 was adopted with these conditions. However, the quantity of oxine used 
may need to be increased further for larger activity labelling, in light of experiments 
described below. 
Determination of radiochemical purity of [89Zr]-Zr(oxinate)4 can be done by 
ITLC or solvent extraction. ITLC-SG (stationary phase) and ethyl acetate (mobile 
phase) were used to develop the radio-chromatogram of [89Zr]-Zr(oxinate)4 which 
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demonstrated an Rf of 0.9 whereas the Rf of free (“neutralised”) 89Zr was 0. Rf of 
[89Zr]-Zr(oxinate)4 was compared with cold zirconium oxine complex (dissolved in 
DMSO) which gave a corresponding Rf value of 0.9. In the solvent extraction 
procedure, chloroform and PBS were used as organic solvent and aqueous solution, 
respectively, to examine the percentage of hydrophilic impurity. The lipophilic 
complex, [89Zr]-Zr(oxinate)4 can be determined from the activity found in the 
chloroform fraction whereas activity of the other impurities can be determined from 
the PBS fraction. For the (previously) commercially available [111In]-In(oxinate)3, 
solvent extraction is a standard procedure to determine labelling efficiency of the 
complex in the U.S. and European pharmacopeia. Acceptable radiochemical purity of 
[
111
In]-In(oxinate)3 used in clinical work according to the pharmacopeia is not less than 
90%. However, [
111
In]-In(oxinate)3 complex is commercially available and ready to 
use so the process to determine labelling efficiency and shelf life of product is the 
responsibility of the manufacturers. Although high performance liquid chromatography 
(HPLC) has been widely used to carry out radiochemical purity testing for a range of 
radiopharmaceuticals especially in research, for the lipophilic complexes of oxine it 
has never been reported. HPLC might not be suitable for determining radiochemical 
purities of the radiotracers oxine complex due to dissociation and hence separation of 
oxine from indium during passage down the column leading to unreliability.   
Oxine is well known as a chelator for metal ions. Lipophilic complexes of 
oxine have been investigated with a number of radionuclides such as Co-57 (145), Fe-
59 (145), Ga-67 (145), Tl-201 and Ga-68 (97) as tracers for labelling cells.  Different 
amounts of oxine have been utilised to complex with radionuclides. For instance in the 
early research on [
111
In]-In(oxinate)3, 150 g of oxine in ethanol was used to complex 
with [
111





prepared with 50 g of oxine. In other research 150 g oxine was used to complex 
with 
68
Ga (97).  Since oxine has antimicrobial properties then it might be toxic to the 
cells and possible damage the labelled cells would correlate with the amount of oxine. 
To avoid this effect therefore researchers have been attempted to keep the quantity of 
oxine as low as possible. In our solvent extraction technique 500 g of oxine was 
needed to complex with 
89
Zr to achieve adequate labelling yield. This amount of oxine 
is higher than in [
111
In]-In(oxinate)3 commercially. Therefore an alternative procedure 
to do the reaction in aqueous solution might be able to reduce quantity of oxine, 
similar to the commercial [
111
In]-In(oxinate)3. However, the chemical form of 
89
Zr is 
different from that of 
111
In and the ligand metal affinity is likely to be different, so 
further optimisation is needed.  
The production of [89Zr]-Zr(oxinate)4 by using solvent extraction technique was 
reproducibly above 75% when lower activity was used in the experiments of method 
development (1–2 MBq) or for in vitro biological evaluation (around 5-10 MBq) was 
initially used. However, the results of synthesis [89Zr]-Zr(oxinate)4 for the in vivo 
studies using larger activities (40-80 MBq) showed significantly lower radiochemical 
yields were obtained. From Table 3.3 labelling efficiency of [89Zr]-Zr(oxinate)4 was 
significantly less than expected and was variable. Among many productions, a similar 
pattern was observed. Typically the first extraction of [89Zr]-Zr(oxinate)4 gave lower 
activity compared to activities of the complex produced from the subsequent 
extractions. This could be explained by the increased quantity of oxalate present in 
larger volumes, possibly acting as a competing ligand. Initial extractions with 
chloroform may remove some of the oxalic acid allowing more efficient complexation 
by oxine in subsequent extractions. From these results, although the synthesis 
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successfully produced [89Zr]-Zr(oxinate)4 with acceptable quality, labelling efficiency 
of the high initial activity is still problematic.  
A different procedure to synthesise oxine complexes in the aqueous phase with 
oxine in ethanol instead of chloroform were reported (97, 147). In that procedure, the 
lipophilic oxine complex was precipitated and then separated from the mixture. 
Subsequently, organic solvent was used to extract the oxine complex from the 
precipitate (145). This alternative procedure might improve labelling efficiency of 
[89Zr]-Zr(oxinate)4 however further investigation is required. 
Junfeng Yu et al. reported that to prepare 
90
Y oxine-ethiodol, a therapeutic 
tracer for liver cancer, 
90
Y oxine was labelled by reaction between buffered yttrium-90 
chloride and oxine in either ethanol or chloroform prior to extracting the 
90
Y oxine 
complex in chloroform or dichloromethane (148). The results showed that 
radiolabelling efficiency depended on the solvent used to dissolve oxine; while 
chloroform was not able to produce 
90
Y oxine, about 36% of 
90
Y oxine could be 
produced when ethanol was used as a solvent with the same concentration of oxine. 
This suggests we could apply to our [89Zr]-Zr(oxinate)4 production a procedure to 
replace the solvent in which oxine is dissolved from chloroform to ethanol to improve 
radiolabelling efficiency. However alteration of solvents will required further 
investigation. 
Another issue relates to the solvent (DMSO) which is used to dissolve [89Zr]-
Zr(oxinate)4 complex after evaporation of the chloroform. It would be preferable to 
avoid use of DMSO. In case of standard tracer for labelling cells, [
111
In]-In(oxinate)3, 
in early research it was produced with solvent extraction technique and the final 
product [
111
In]-In(oxinate)3 was dissolved in ethanol. With this procedure, the toxicity 
of ethanol to the labelled cells was a problem and in addition it was time consuming. 
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Moreover, this complex was bound to the container so the final product was obtained 
in lower yield than expected. However, researchers were subsequently able to 
overcome these problems with a procedure to synthesise [
111
In]-In(oxinate)3 in an 
aqueous phase, which was successfully patented in France and USA in the 1980s. This 
formula contained a surfactant which reduced amount of tracer adsorbed to its 
containing glass vial. The aqueous solution can be autoclaved to give sterile [
111
In]-
In(oxinate)3 product suitable for autologous blood cell labelling. Labelling efficiency 
to blood cells was also increased compared with those labelled with [
111
In]-In(oxinate)3 
in ethanol solution.  
The time-course and efficiency of uptake of the synthesised [89Zr]-Zr(oxinate)4 
into 3 different cell lines including mouse macrophage J774, human breast cancer 
MDA-MB-231 and human multiple myeloma eGFP-5T33 was investigated. The 
intracellular transport of [89Zr]-Zr(oxinate)4 was monitored using eGFP-5T33 cells.  
Currently, the imaging of labelled cells is used clinically for diagnosis and 
localisation of infection and inflammation lesions. Infection/inflammation in animals is 
therefore an appropriate model in which to demonstrate new radiolabelling methods. 
However to obtain an adequate amount of white blood cells (WBCs) for radiolabelling, 
10 ml of whole blood from many animal donors is needed.  Due to the rapid growth 
eGFP-5T33 cells, compatible with multiple myeloma mouse model 
(C57BL/KaLwRij), and because it has been investigated in our group for the other 
purposes and they have been genetically modified to express eGFP, these cells offer an 
advantage for use as a model system in the present context.   
The uptake rate of [89Zr]-Zr(oxinate)4 showed a similar pattern in all three cell 
lines used. The radiotracer was moderately transported into the 1 x 10
6
 J774 and 
MDA-MB-231 cells and reached the highest percentage of 23% and 20%, respectively, 
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while 1 x 10
6
 eGFP-5T33 cells showed lower uptake rate at approximately 10%.  
Meanwhile, the uptake of neutralised 
89
Zr was determined in order to determine 





Zr) could be taken up by the cells. As expected, relatively low uptake of free 
89
Zr into J774 and MDA-MB-231 cells was observed. Although the uptake of free 
89
Zr 
into eGFP-5T33 was not determined, low uptake rate was expected, although different 
uptake rates among cell lines might be cell type dependent which is similar to other 
radiotracers for labelling cells.  
Non-specific binding of [89Zr]-Zr(oxinate)4 to materials used in the vessels and 
equipment was determined in parallel with cellular uptake experiments, because 
preliminary work of lipophilic 
64
Cu complexes had identified problems with 
adsorption to plasticware. Tracer was found to negligibly bind to the glass reaction 
tubes and the apparent percentage of tracer taken up by the cells was not affected by 
non-specific binding. Therefore the results indicated that [89Zr]-Zr(oxinate)4 was 
successfully taken up in a range of cell types, although the efficiency of uptake 
(percent) was in general lower than observed for [
111
In]-In(oxine)3 in parallel cell 
samples. 
The efflux rate of [89Zr]-Zr(oxinate)4 in 3 cell lines after labelling was also 
investigated. At 24 hr after labelling, the retained activity in J774, MDA-MB-231 and 
eGFP-5T33 cells was found to be 91%, 83% and 72%, respectively. The retention 
activity of [
111
In]-In(oxinate)3 in the labelled cells in both cell lines, J774 and MDA-
MB-231, was significantly lower at approximately 52% and 44% in the labelled cells 
24 hr post labelling. At 24 hr, the retention of [89Zr]-Zr(oxinate)4 labelled J774 and 
MDA-MB-231 cells was statistically significantly greater than that of [
111
In]-
In(oxinate)3 with p-values of 0.008 and < 0.001, respectively. 
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  Prolonged retention of activity by labelled cells is advantageous because it 
allows imaging to follow the labelled cells for longer period of time, and the images 
are less impaired by the presence of radioactivity that is not bound to the administered 
cells. This is important especially in the application of tracking labelled therapeutic 
cells or stem cells where it is desirable to track the cells over a longer periods 
compared to autologous white blood cell labelling.  
For labelling eGFP-5T33 experiment, the labelling procedure was modified to 
minimise differences of geometry among the samples before measuring with dose 
calibrator. As shown in Table 2-4, the cell pellets were resuspended with culture 
medium to a volume of 12-15 ml prior to measuring the activities instead of directly 
measuring the activities of only the cell pellets compared to the activity in the 
supernatant (including washing buffer). The eGFP-5T33 cells were labelled with 
[89Zr]-Zr(oxinate)4 and [
111
In]-In(oxinate)3 with either high or low activity in order to 
study the effect of radioactivity levels on labelling yield. The percent labelling yields 
of both tracers were similar despite using different activities. Taken together, it was 
found that the initial activity of [89Zr]-Zr(oxinate)4 and [
111
In]-In(oxinate)3 did not 
affect the labelling yield in eGFP-5T33 cells. However, the number of cells was an 





 and 1.3 x 10
7
, the labelling yield was improved with both [89Zr]-Zr(oxinate)4 
or [
111
In]-In(oxinate)3. Therefore these finding suggest, predictably, that labelling 
yields should be enhanced by increasing the number of cells but not by varying the 
initial amount of radioactivity.  
From the results of white blood cell labelling, WBCs were consistently labelled 
with [89Zr]-Zr(oxinate)4 in the range of 15.58% and 17.67% (mean 16.58 ± 1.05 %). 
These cell labelling efficiencies are lower than those of [
111
In]-In(oxinate)3. 24 hr after 
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labelling, [89Zr]-Zr(oxinate)4 showed higher retention in the labelled cells than [
111
In]-
In(oxinate)3. Greater than 85% of [
89Zr]-Zr(oxinate)4 was retained in the labelled cells 
whereas retention in [
111
In]-In(oxinate)3 labelled WBCs was around 75% (based on 
package insert of [
111
In]-In(oxinate)3, Amersham Healthcare) at the same time point.  
  The uptake in the other cell types related to the applications of tracking labelled 
cells such as T-cells, dendritic cells and stem cells should be further investigated. 
Another aspect that needs further study prior to translating this method to clinical 
application is whether [89Zr]-Zr(oxinate)4 can alter cell proliferation and function, 






 From our study, the production of 
89
Zr lipophilic complex, [89Zr]-Zr(oxinate)4, 
was successfully accomplished using a solvent extraction technique. According to the 
results of optimisation of the amount of oxine and reaction time, 500 g of oxine was 
chosen to reach the highest labelling yield and the reaction was performed for 15 min, 
generating radiotracer with acceptable labelling yield if low activities were used. The 
quality of [89Zr]-Zr(oxinate)4 was adequate to use in either in vitro or in vivo studies. 
However, radiolabelling efficiency when high activity (>40 MBq) is required for in 
vivo imaging, yields are lower and the quantity of oxine, the choice of solvent and 
overall production procedures need to be improved and opportunities to improve these 
in future have been identified. 
[89Zr]-Zr(oxinate)4 is moderately taken up by several cell types such as 
macrophages, breast cancer cells and multiple myeloma cells including human white 
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blood cells.  High retention of [89Zr]-Zr(oxinate)4 within the labelled cells (compared 
to[
111
In]-In(oxine)3) was shown over all cell types evaluated. It is therefore suggested 
that [89Zr]-Zr(oxinate)4 is a promising tracer for labelling cells due to consistent higher 
retention within the labelled cells than the standard radiotracer ([
111
In]-In(oxinate)3), 




Cu-PTSM). Moreover, translation of [89Zr]-
Zr(oxinate)4 to be used in the clinical practice would be possible and with low 
regulatory barriers because the ligand, oxine, is established as a gold standard 





Chapter 4: In vivo study of [89Zr]-Zr(oxinate)4 
4.1 Introduction 
 Zirconium-89, a long-lived PET radionuclide, has been the subject of increased 
interest in recent years for use in the field of immuno-PET imaging. The physical 
properties of 
89
Zr offer advantages for molecular imaging using antibodies which 
require long periods of time for accumulation into the targets and also to achieve 
optimum ratio between target (tissue or organ lesions) and background. 
 In the same period, Heuveling et al. and Keliher et al. reported on the feasibility 
of 
89
Zr labelled nanocolloidal albumin and dextran nanoparticles to detect sentinel 
lymph node and macrophages homing tissues, respectively, in animals (149, 150). 
Subsequently, a preliminary study in patients was presented from the same group. The 
sentinel lymph node detection in cancer patients with 
89
Zr labelled nanocolloidal 
albumin with PET illustrated superior sensitivity and the resolution compared to 
99m
Tc 
labelled nanocolloidal albumin with SPECT (151). The potential advantages of this 
superior imaging capability of 
89
Zr in the field of cell tracking have not yet been 
exploited for cell tracking. 
In the late 1980‟s Radl et al. reported that multiple myeloma (MM) 
spontaneously arises in ageing C57Bl/KaLwRij mice; they subsequently described and 
characterised different subtypes of MM such as 5T2, 5T33 cells (152). Disease can be 
induced and also transferred to another C57Bl/KaLwRij mouse by simple intravenous 
inoculation with 5T MM cells. In the 5T models of MM myeloma cells are localised in 
the bone marrow (BM), spleen and liver (haematopoietic organs) of inoculated mice. In 
2000, Vanderkerken and colleagues found that radiochromium (Cr-51) labelled 5T2 
cells predominantly accumulated in the liver, spleen and BM while activity released by 
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radiolabelled cells was observed in the kidneys and urine (153). Alici et al. established 
an enhanced green fluorescent protein (eGFP) transfected 5T33 cell line that could be 
maintained in vitro (154). The homing pattern of eGFP-5T33 cells could then be 
studied by FACS analysis of organ homogenates (and detection of the endogenous 
eGFP signal) which proved to be a more convenient method than previous approaches 
relying on immunostaining and subsequent FACS analysis. Tissue distribution of 
eGFP-5T33 cells confirmed that BM, spleen and liver were the main target tissues for 
5T33 MM cells. [
89
Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells are expected to present 
an identical homing pattern in C57BL/KaLwRij mice.  
 
4.2 Aims 
The aims of this set of experiments were to build on the radiochemical and in 
vitro studies in the previous chapter to track the fate of [
89
Zr]-Zr(oxinate)4 labelled 
eGFP-5T33 cells in the murine multiple myeloma model, C57BL/KaLwRij, comparing 
with those of [
111
In]-In(oxinate)3 labelled cells, and thereby evaluate the 
89
Zr-method as 
a PET approach to cell tracking. We also set out to determine the viability of labelled 
cells in vivo and their retention of the radiolabel, using ex vivo tissue counting of mice 
injected with labelled cells. The in vivo stability of and radioactivity counting in FACS-
sorted [89Zr]-Zr(oxinate)4 labelled cells ex vivo, a new technique to determine the 






 4.3.1 In vivo tracking of labelled eGFP-5T33 in multiple myeloma model 
Throughout this section, in vivo imaging and ex vivo tissue counting was 
carried out in murine multiple myeloma model, C57BL/KaLwRij strain, in which 
myeloma can be induced with 5T33 cells via intravenous injection. 5T33 cells, 
transfected with enhanced green fluorescent protein to give a new cell line derivative 
eGFP-5T33, used in our experiments was provided by Dr Yolanda Celle (University of 
Roehampton) (originally provided by Dr. Abedi-Valugerdi, Division of Haematology, 
Department of Medicine, Karolinska Institute at Karolinska University Hospital, 
Stockholm, Sweden). This cell line has been used for a number of studies at the 
Department of Haematological Medicine, King‟s College London. A report from Alici 
and colleagues indicated that eGFP-5T33 cells home to the bone marrow, spleen and 
liver (154). Therefore in this study these cells were labelled with the 
89
Zr tracer, [89Zr]-
Zr(oxinate)4, to carry out in vivo biodistribution with both imaging and tissue 
distribution counting, in comparison with 
111
In labelling. 
4.3.1.1 In vivo study, Series 1  
In this part of the study we aimed to track [89Zr]-Zr(oxinate)4 labelled cells in 
vivo in the 5T33 murine multiple myeloma model in C57BL/KaLwRij mice and 
compare these results to in vivo tracking of [
111
In]-In(oxinate)3 labelled cells in the 
same model. [
111
In]-In(oxinate)3 is a well-established clinical standard radiotracer for 
cell tracking. The tissue distribution of labelled cells was also determined (ex vivo 
tissue counting). The fate of lysed (dead) eGFP-5T33 cells that had previously been 
labelled with either [89Zr]-Zr(oxinate)4 or [
111
In]-In(oxinate)3 was also investigated.  
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eGFP-5T33 cells were dispensed from the culture flask, and cell concentrations 
and viabilities were measured as described in Chapter 3. Cell suspensions containing 4 
x 10
7
 cells and 2.5 x 10
7
 cells were aliquoted into 50 ml Falcon tubes (one tube with 
4.0 x 10
7
 cells and two tubes with 2.5 x 10
7
 cells).  Cells were washed with PBS twice 
(vide supra). After the last washing step, supernatants were discarded and cell pellets 
were resuspended in 1 ml of serum free medium. 20 MBq of [
111
In]-In(oxinate)3 was 
used to label 4.0 x 10
7
 cells and 19 MBq and 21 MBq of [89Zr]-Zr(oxinate)4 were used 
to label each of 2.5 x 10
7
 cells. Both radiotracers were diluted in 2 ml of serum free 
medium and added dropwise to the cell suspensions followed by swirling every 10 min. 
After incubation (room temperature) with radiotracers for 30 min, labelled cells were 
washed following the same procedure as described in Chapter 3 to eliminate 
radioactivity weakly bound or released by radiolabelled cells.  
Labelled cells were resuspended in sterile PBS for injection. At this stage 
89
Zr 
labelled cells from different extractions of [89Zr]-Zr(oxinate)4 were pooled then activity 
retained in the labelled cells was measured in the dose calibrator as well as for [
111
In]-
In(oxinate)3 labelled cells. Meanwhile cell viabilities and cell concentrations were 
determined; washed labelled cells were diluted with PBS to get the final cell 
concentration of around 10
7
 viable cells/100 l for administration into animals. 89Zr 
labelled cells prepared in this experiment were used for in vivo PET tracking of live 
labelled cells and dead labelled cells and for ex vivo organ biodistribution in 4 mice 
while cells labelled with 
111
In were only used to carry out SPECT tracking of live cell 
and ex vivo tissue counting experiments. [
111
In]-In(oxinate)3 labelled lysed (dead) 
eGFP-5T33 cells was separately labelled. 6 MBq of [
111
In]-In(oxinate)3 was an initial 
activity added into around 7 x 10
6 
washed eGFP-5T33 cells for labelling. The labelling 
procedure was same as described above. 
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The study of radiolabelled cell lysates was assessed as a model for radioactivity 
released from dead and dying cells in vivo. In order to study fate of radiotracers in the 




Zr(oxinate)4) were aliquoted into microcentrifuge tubes. In order to lyse the cells, 
labelled cells were centrifuged, supernatant discarded and cells subsequently underwent 
a repeated process of freezing in liquid nitrogen, thawing at 37
o
C and vortexing. This 
procedure was repeated three times. PBS was used to re-suspend the lysed (dead) 
labelled cells. To avoid cell debris aggregation, cell lysates were repeatedly withdrawn 
into an insulin syringe fitted with a 29 gauge needle several times. Lysates were then 




89Zr]-Zr(oxinate)4 labelled cell samples 
were withdrawn in insulin syringes fitted with a 29 g needle (for ex vivo tissue 
counting) or into a 1 ml syringe (for imaging). Cannulae fitted with 27 gauge needles 
were altered so that they could be used for injecting small animals. The original tubing 
was removed and replaced by extended tubing. Tubing was filled with saline for 
injection and air bubbles eliminated.  
In vivo experiments in this chapter were performed under project licence (PPL) 
70/7238 (in vivo imaging in cancer models) and personal investigator licence (PIL) 
70/23500, held by Prof. Philip Blower and Dr. Levente Meszaros, respectively. 
Experimental protocols and animal handling fully complied with the corresponding 
PPL, PIL and Home Office guidelines. Seven weeks old male C57BL/KaLwRij mice 
were purchased from Harlan UK. For each tracer one mouse was used for in vivo 
imaging of labelled cells, 4 mice for ex vivo tissue counting and 1 mouse was used for 
imaging dead radiolabelled cells (n=6/tracer, 12 mice in total). Mice had ad libitum 
access to water and diet throughout the study. 
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Mice were transferred from biological services unit (BSU) to the pre-clinical 
laboratory 15-30 min before the experiments to let them acclimatise.  
4.3.1.1.1 Injection of labelled cells for imaging 
 In vivo images throughout this chapter were acquired in nanoSPECT/CT Plus 
system (Mediso, Hungary) and nanoScan PC in vivo pre-clinical PET/CT imager 
(Mediso, Hungary). 
Mice were anaesthetised with 2-3% isoflurane in O2 in an induction box then 
transferred to the scanner bed where anaesthesia was maintained (isoflurane, 1.5-2.0% 
in O2). Mice were monitored using a respiratory pad. The injection site was wiped with 
a tissue impregnated in 70% ethanol. One of the lateral tail veins was cannulated. A 
PET or SPECT scan was started and ca. 1 minute later the labelled cells or cell lysate 
were injected. Injected activities of [
111
In]-In(oxinate)3 labelled live cells, dead cells 
and 
89
Zr labelled live cells and lysed cells were 10 MBq, 3.5 MBq, 6 MBq and 2.0 
MBq, respectively.  PET scans were acquired continuously for 4 hr for [89Zr]-
Zr(oxinate)4 labelled live eGFP-5T33 cells and 2 hr for [89Zr]-Zr(oxinate)4 labelled 
lysed eGFP-5T33 cells. Mice injected with [
111
In]-In(oxinate)3 labelled live cells and 
lysed cells were scanned continuously for 3.5 hr and 30 min respectively. Each SPECT 
and PET scan was followed by a whole-body CT scan (55 kV X-ray source, 1000 ms 
exposure time and 180 projections). At the end of the scanning session each mouse was 
transferred to a recovery cage. After recovery, imaged mice were transferred to their 
home cage and returned to the BSU. Subsequent scanning sessions were performed as 
follows: 24 hr, 48 hr, and 168 hr post-inoculation for both of radiotracers (live cells). In 
the studies with radiolabelled “lysed (dead) cells”, the mouse injected with 89Zr 





In]-In(oxinate)3 labelled lysed cells was only imaged one day post 
injection. At the end of last scan all injected mice were culled by cervical dislocation. 
For the ex vivo tissue biodistribution study, each radiotracer was evaluated in 3 




89Zr]-Zr(oxinate)4 were withdrawn in insulin syringes fitted with 
a 29 gauge needle. 1.7 MBq of [
111
In]-In(oxinate)3 and 0.9 MBq of [
89Zr]-Zr(oxinate)4 
were used per mouse. Due to the rapid sedimentation of labelled cells cell suspensions 
were mixed well before dispensing. This way we could make sure that activity of each 
radiotracer in each syringe was nearly identical. Activities in the syringes were 
measured in the dose calibrator. In addition before and after injection all syringes were 
weighed. Four syringes per compound were used to inoculate mice for biodistribution 
study and one syringe for each compound (prepared the same way as those used for 
inoculations) was kept as a calibration standard for the gamma counter. For 
inoculations mice were placed in a heating box (T=37
o
C) for 5-10 minutes to evoke 
vasodilation then placed in a restrainer for inoculation. The tails were wiped with an 
ethanol-impregnated tissue, then labelled cells were injected via a lateral tail vein. Mice 
were released then, once bleeding at the injection site had stopped, placed in their home 
cage and subsequently transferred to the BSU.  
Calibration standards were prepared as follows. Labelled cells in the standard 
syringe were injected into a tube and diluted to a final volume of 1 ml in PBS. Then 
this solution was dispensed into scintillation vials as follows: 250 l, 125 l, 62.5 l, 
31.25 l, 15.63 l, 7.81 l, 3.90 l and 1.95 l. In order to avoid measurement error 
from geometry, PBS was added into each tube to make up solutions to 500 l in each 




In order to determine tissue distribution of radioactivity in the inoculated mice, 
7 days post inoculation, mice were culled by CO2 asphyxiation. Mice were dissected 
and the following organs collected: heart, lungs, liver, spleen, stomach, small intestine, 
large intestine, kidneys, muscle, femur, salivary glands, tail and 50-150 l of blood. 
Organs were weighed and gamma counted, %ID and %ID/g were calculated. To ensure 
measurement accuracy, samples with a measurement dead time exceeding 20% were 
left to decay and measured later. The organ-to-organ uptake ratios were calculated 
among the main target organs (the liver, the spleen, the femur and the kidneys). 
4.3.1.2 In vivo study, Series 2 
Due to a fatal thermal injury of a mouse injected with [89Zr]-Zr(oxinate)4 
labelled cells in the previous section, the study had to be repeated. In this series the 
imaging protocol was extended to 14 days. 
Based on the images we obtained with the mice injected with radiolabelled and 
subsequently lysed cells we suspected that cell lysis in those studies (reported in Series 
1) was incomplete. Therefore we decided to repeat these experiments; with an 
improved protocol to lyse the labelled cells.   
[89Zr]-Zr(oxinate)4 in this study was synthesised using the protocol for in vivo 
experiments (described in Chapter 3). 2 x 10
7
 cells, 3.5 x 10
7 
cells and 2 x 10
7
 cells of 
eGFP-5T33 cells were added with 8.4 MBq, 15.9 MBq and 8.3 MBq of [89Zr]-
Zr(oxinate)4, respectively, to obtain the radiolabelled cells. The procedures for washing 
myeloma cells and labelling the cells were the same as described in series 1. 
Subsequently, 3 batches of labelled cells were pooled before measuring the activity, 
cell concentration and viability. [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells were 
134 
 
diluted with PBS and withdrawn into a 1 ml syringe for subsequent injection via 
cannula.   
To prepare the 
89
Zr labelled cell lysates the following process was adopted. 
eGFP-5T33 cells labelled with [89Zr]-Zr(oxinate)4 were flash frozen in liquid N2 then 
subsequently incubated at 95
o
C for 5 min in a heatable shaker. The cell pellet was then 
vigorously mixed with a vortex mixer. The process was repeated 3 times. The resulting 
“cell lysate” was dispensed in a 1 ml syringe for subsequent injection via cannula. 
In vivo imaging of labelled live cells was performed for the first 2 hr, 24 hr, 48 
hr, 72 hr, 168 hr (7days) and 336 hr (14 days) post inoculation. Mice injected with 
labelled cell lysate were imaged for 2 hr after injection then at 24 hr post-injection.  
4.3.1.3 In vivo study, Series 3 
 Further to unsuccessful (to completely lyse the labelled cells) of imaging lysed 
(dead) [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells in the in vivo study Series 2, in this 
experiment we took extra care for the preparation and injection of radiolabelled lysed 
cells. 7 x 10
6
 multiple myeloma cells were dispensed for labelling with radiotracer. 
Following washing steps as described previously, 7.2 MBq of [89Zr]-Zr(oxinate)4 was 
used to label the cells as described above.  The labelled cell pellet (3 x 10
6
 cells for 2.6 
MBq) was frozen in liquid nitrogen and thawed at 95
o
C 3 times. The [89Zr]-Zr(oxinate)4 
labelled cell lysate (in PBS) was repeatedly withdrawn into a 1 ml syringe fitted with 
an 18 gauge needle. This was then repeated using decreasing needle width (21 gauge, 
26 gauge and 27 gauge respectively). With this process we aimed to disintegrate 
aggregates present in the suspension. After this process, the cell lysate was withdrawn 
in an insulin syringe before injection into the mouse. Around 1 MBq of dead labelled 
cell lysate were injected i.v. via the tail vein. PET/CT images were acquired after 
injection for 30 min and 1 day post injection.  
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 Moreover in this study, biodistribution of 
89
Zr labelled cells was investigated at 
earlier time points to investigate any change in initial tissue distribution with time. 45 x 
10
6
, 45 x 10
6
 and 25 x 10
6 
eGFP-5T33 cells were withdrawn from the culture flask into 
50 ml Falcon tubes. Cells were washed and 16.5 MBq, 14.8 MBq and 6.98 MBq of 
[89Zr]-Zr(oxinate)4 were added to label cells, respectively, as described above. Pooled 
radiolabelled cells in PBS were measured in a dose calibrator and then drawn up into 
insulin syringes which then contained approximately 2.5 x 10
6
 cells labelled with 0.9 
MBq 
89
Zr. Tissue distribution of labelled cells was determined in 3 or 4 mice for each 
time point. Injected mice were sacrificed at 9 hr, 24 hr and 48 hr after intravenous 
injection. The desired tissues or organs were dissected and counted in the gamma 
counter (together with their injected activity standard). 
4.3.1.4 In vivo study, Series 4 
 Cell sorting technique is a useful tool to separate cell samples depending on 
their phenotypes. In this section, fluorescence activated cell sorting (FACS) was used 
to assess whether the radiolabel in vivo remained in the labelled cells or was released 
into the organ homogenate cells. Based on the previous study for in vivo biodistribution 
of [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells, the main accumulation organs were 
liver, spleen and skeleton. Therefore, these organs of mice injected with [89Zr]-
Zr(oxinate)4 labelled cells were homogenised to obtain the cells for subsequent FACS 
sorting. 
[89Zr]-Zr(oxinate)4 was synthesised and radiochemical purity was determined 
before using in the study. eGFP-5T33 cells were labelled with [89Zr]-Zr(oxinate)4 in the 
same manner described in the Series 1. Six multiple myeloma mice were used in this 
study and prepared for the injection as described above. An aliquot of 1.5 MBq of 
[89Zr]-Zr(oxinate)4 labelled cells (1 x 107 cells) was diluted to 200 l with sterile PBS 
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and injected intravenously (lateral tail vein). Then injected mice were allowed to 
recover and returned to BSU. At 2 days and 7 days after inoculation, for each time 
point 3 mice were culled by CO2 asphyxiation. The liver, spleen and femora were 
harvested. Each liver and spleen was homogenised by using syringe puncture and 
gently filtered through a 40 m cell strainer (BD, USA) in order to remove larger cell 
aggregations. The organ homogenates were diluted in ice-cold FACS buffer (PBS with 
1% v/v FCS, 2 M EDTA). Femora were cleaned of muscle and joints were cut off. 
The bone marrow cells were flushed with ice-cold FACS buffer and filtered through a 
40 m cell strainer. Cells were counted by staining with trypan blue in a 
haemocytometer before diluting with FACS buffer to a concentration of 10
7
 cells/ml. 
Samples were kept on ice in FACS buffer and sorting experiments were performed 
within 6 hr after preparation. 
 The samples were analysed and sorted on a BD FACSAria III cell sorter (BD, 
USA). The samples were monitored for the expression of green fluorescence protein on 
FITC channel in order to discriminate between injected eGFP-5T33 cells and organ 
homogenate cells. To confirm the GFP expression by eGFP-5T33 cells (which had 
undergone semi-continuous culturing in our lab), cells were made into suspension 
using FACS buffer for a concentration of 1 x 10
5
 cells/ml and analysed with flow 
cytometer in comparison to those of negative GFP expression cells, J774 cells, to show 
contrast with the GFP cells and hence the validity of the FACS experiments. Then each 
sample was sorted based on GFP expression to collect either 10,000 or 25,000 GFP 
positive cells and an equal number of GFP-negative cells in the same sample were also 
sorted, with the positive and negative samples collected in separate tubes. The count 




4.3.1.5 In vivo study, Series 5 
 In order to study the biodistribution pattern of the tracer itself (i.e. not 
incorporated into cells), the injection of [89Zr]-Zr(oxinate)4 in the multiple myeloma 
mouse was conducted. [89Zr]-Zr(oxinate)4 was synthesised using the protocol described 
in Chapter 3. Four MBq of [89Zr]-Zr(oxinate)4 was diluted in 100 l sterile PBS and 
placed in an  insulin syringe for the injection. A mouse was prepared for the injection 
as for Series 1-4. The radiotracer was intravenously injected via the tail vein prior to 
PET/CT imaging with nanoScan PC for 30 min. After imaging, the mouse was allowed 
to recover and returned to the BSU. Further imaging was performed at 24 hr post 
administration. 
4.3.1.6 In vivo study, Series 6 






Zr oxalate) accumulation in organs of 
C57BL/6J mice was determined for comparison with that of labelled cells and oxine 
complex. Ex vivo tissue counting of the
 
mice was determined at day 2 and day 7 after 
inoculation. 
In this set of studies, to prepare the tracer, 5 MBq of 
89
Zr in oxalic acid was 
neutralised with 1 M sodium carbonate and 0.1 M ammonium acetate was added to 




was adjusted to 100 l with 
0.9% normal saline before dispensing into an insulin syringe. Then the mouse was 




in a lateral tail 
vein then transferred to the nano-PET scanner bed and scanned for 30 min. Further in 
vivo imaging was carried out at 24 hr post-injection.  
 For ex vivo tissue counting, approximately 9 MBq of 
89
Zr in oxalic acid was 
neutralised with 1 M sodium carbonate to (reach pH around 7) and 0.1 M ammonium 
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acetate was added to get the final activity concentration of 1 MBq/100 l. 100 l of the 
above solution was injected into each mouse (n = 3 for each time point) as described 
for Series 1 above. Three mice were sacrificed at each time point (day 2 and day 7 after 
tracer injection) by CO2 asphyxiation, mice were dissected, relevant organs collected, 
weighed and gamma counted and uptake was calculated. 
 
4.4 Results of the in vivo tracking of radiolabelled cells 
4.4.1 In vivo study, Series 1 
Initial activities added to cells to label them in two batches were 19 MBq and 
21 MBq. The washed radiolabelled cells from these 2 separate labellings were pooled 
together. The final activity was 14 MBq (in 2.4 x 10
7
 cells) so cell labelling yield was 
around 35% while viability of labelled cells was 90%. After labelling these eGFP-
5T33 cells with [89Zr]-Zr(oxinate)4 the cells were dispensed as follows: 6 MBq/1.0 x 
10
7 
cells were injected for PET imaging, 2 MBq/3 x 10
6
 cells for were treated for 
imaging dead cells and 0.6 MBq/ 1 x 10
6
 cells were used for ex vivo tissue counting in 
4 mice. The activity of [
111
In]-In(oxinate)3 labelled cells was 18.8 MBq (94% cell 
labelling yield), and 10 MBq/1 x 10
7
 cells and 1.7 MBq/1.7 x 10
6
 cells were injected 
for in vivo imaging and ex vivo tissue counting, respectively. For the study with [
111
In]-
In(oxinate)3 labelled lysed cells another batch of cells were labelled. The labelling 
yield was 78%; 5 MBq of [
111
In]-In(oxinate)3 labelled cells were obtained. After the 
labelled cells had been lysed, 3.5 MBq/2.1 x 10
6
 cells were dispensed into an insulin 
syringe fitted with a 29 g needle and subsequently injected i.v. into a mouse for 
imaging. All labelled cells whether with [89Zr]-Zr(oxinate)4 or [
111
In]-In(oxinate)3 
showed cell viability over 90% using trypan blue staining for lived-cells experiment. 
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The mouse injected with [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells was 
imaged for 30 min after injection; subsequent scans were acquired at 24 hr and 48 hr, 
after inoculation. At 4 days post-injection a serious injury unrelated to the cell 
inoculation was discovered hence the mouse had to be culled and the study was 
terminated. For the early time point, [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells were 
transiently accumulated in the lungs, heart and in blood pool. Soon after that, activity 
began to clear from the lungs to the liver and spleen and some was also detected in the 
skeleton. On the subsequent images at 24 hr, activity had completely cleared from the 
lungs whereas high activity remained localised in liver, spleen and bone. Due to the 
injury affecting the right hand side of the animal activity distribution was asymmetric 
(Figure 4.1) suggesting that progressed tissue necrosis occurred; this was later 




                    
                              30 min                         24 hr                          48 hr                                
Figure 4.1: Biodistribution of [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells after 
injection into multiple myeloma mouse model, at 30 min, 24 hr and 48 hr post 
administration. Asymmetry of the biodistribution was observed since 24 hr after 
injection. 
After injection of [
111
In]-In(oxinate)3 labelled eGFP-5T33 cells the mouse was 
scanned for the first 30 min. Subsequent images were acquired at 2 hr, 24 hr, 48 hr and 
168 hr after injection as shown in Figure 4.2. Most of the injected activity in the early 
hours was retained in the lungs and blood pool before clearing to the liver and spleen. 
After 24 hr accumulation activity in the bones was observed. At day 7 after injection, 
activity still remained in the liver, spleen and bones. Some activity was detected in the 
kidneys which might be caused by excretion of 
111
In from the dying labelled cells. 
Images suggested that the radiolabel was mostly retained by the cells for at least 7 





        30 min                2 hr       24 hr  48 hr       168 hr
   
Figure 4.2: Tissue distribution of [
111
In]-In(oxinate)3 labelled eGFP-5T33 cells in 
C57BL/KaLwRij mouse. SPECT/CT images were obtained at 30 min, 2 hr, 24 hr, 48 




The images obtained with lysed [
111
In]-In(oxinate)3 labelled eGFP-5T33 cells 
24 hr after injection exhibited similar pattern to images obtained with live cells. 
Activity mainly accumulated in the liver, spleen and skeleton. However significantly 
more activity in the kidneys was observed (Figure 4.3).  
                        
 
                                 
               1 hr                24 hr 
 
Figure 4.3: Biodistribution of [
111
In]-In(oxinate)3 labelled eGFP-5T33 cell lysate in 




           Lysed [89Zr]-Zr(oxinate)4 labelled cells were imaged similarly. Images (Figure 
4.4) acquired 1 day post-injection the activity showed activity in the liver, spleen and 
bone marrow and also elevated activity in the kidneys was observed compared to 
injected live cells. This was similar to that of lysed [
111
In]-In(oxinate)3 labelled cells. 
 
                                         
                                                    30 min                            24 hr 
Figure 4.4: Biodistribution of [89Zr]-Zr(oxinate)4 labelled lysed eGFP-5T33 in a 
C57BL/KalwRij mouse after inoculation for 30 min and 24 hr.   
 For ex vivo tissue counting, 0.9 MBq of 
89
Zr oxine or 1.7 MBq of [
111
In]-
In(oxinate)3 labelled cells were injected intravenously into C57BL/KaLwRij mice. 
Seven days after injection mice were culled, major thoraco-abdominal organs, a femur 
and thigh muscle was dissected for subsequent gamma counting. Biodistribution 
results of [89Zr]-Zr(oxinate)4 and [
111
In]-In(oxinate)3 labelled cells are summarised in 





Biodistribution of radiolabelled eGFP-5T33 cells 





Zr oxine labelled 
eGFP-5T33 cells (n=3) 
111
In oxine labelled  











0.04 ± 0.01 0.24 ± 0.04 0.11 ± 0.02 0.71 ± 0.12 
 
Lungs 
0.10 ± 0.01 0.35 ± 0.04 0.20 ± 0.01 0.66 ± 0.05 
 
Liver 
59.83 ±5.97 50.58 ± 8.87 44.94 ± 3.41 33.43 ± 2.09 
 
Spleen 
7.93 ± 0.79 129.5 ± 26.5 4.44 ± 0.34 71.65 ± 6.85 
 
Stomach 
0.13 ± 0.05 0.43 ± 0.12 0.19 ± 0.03 0.66 ± 0.14 
 
Small intestine 
0.17 ± 0.07 0.17 ± 0.07 0.43 ± 0.11 0.43 ± 0.11 
 
Large intestine 
0.18 ± 0.09 0.17 ± 0.08 0.56 ± 0.15 0.45 ± 0.07 
 
Kidneys 
0.97 ± 0.05 2.64 ± 0.39 4.03 ± 0.41 9.89 ± 0.64 
 
Muscle 
0.02 ± 0.002 0.15 ± 0.02 0.05 ± 0.01 0.43 ± 0.05 
 
Femur 
0.89 ± 0.13 10.84 ± 2.54 0.53 ± 0.05 6.01 ± 0.50 
 
Salivary glands 
0.06 ± 0.01 0.39 ± 0.03 0.34 ± 0.09 1.96 ± 0.24 
 
Blood 
0.02 ± 0.003 0.23 ± 0.10 0.02 ± 0.003 0.22 ± 0.06 
 
Table 4.1: Whole body biodistribution of [89Zr]-Zr(oxinate)4 and  [111In]-
In(oxinate)3 labelled eGFP-5T33 cells in multiple myeloma mice, in terms of 
percentage of injected dose (%ID) and percentage of injected dose normalised with 





From the in vivo study Series 1, Table 4.2 shows ex vivo tissue distribution 
results for %ID/g of [89Zr]-Zr(oxinate)4 and [
111
In]-In(oxinate)3 labelled eGFP-5T33 
cells and compares organ-to-organ uptake ratios. A broadly similar pattern of the 
accumulation of the activity in the main organs was noticed for the two radiolabels. 
[
111
In]-In(oxinate)3 was consistently and significantly lower than that of 
89
Zr in liver, 
spleen and femur by factors of 1.5, 1.8 and 1.8, respectively (with p = 0.03, p = 0.02 
and p = 0.03, respectively). On the other hand activity of 
111
In in the kidneys was 
significantly higher than that of 
89
Zr by a factor of 3.75, p < 0.0001). 
 
Biodistribution %ID/g of radiotracers incorporated into eGFP-






Zr oxine (n=3) 
111
In oxine (n=3) 
 
Liver : spleen 
0.39 ± 0.11 0.47 ± 0.05 
 
Liver : femur 
4.69 ± 1.36 5.57 ± 0.58 
 
Spleen : femur 
12.0 ± 3.71 11.9 ± 1.52 
 
Liver : kidneys 
19.2 ± 4.4 3.4 ± 0.4 
 
Spleen : kidneys 
49.1 ± 12.4 7.23 ± 0.8 
 
Femur : kidneys 
4.1 ± 1.1 0.61 ± 0.06 
 
Table 4.2: Tissue distribution of [89Zr]-Zr(oxinate)4 and [
111
In]-In(oxinate)3 
labelled eGFP-5T33 cells, compared organ-to-organ ratio in C57BL/KaLwRij mice at 




Comparison of the activity accumulated in haematopoietic tissues and the 
kidneys, between eGFP-5T33 cells labelled [89Zr]-Zr(oxinate)4 and [
111
In]-In(oxinate)3 
7 days post injection is illustrated in Figure 4.5.  
 
 
Figure 4.5: Graph showing the accumulation of [89Zr]-Zr(oxinate)4 and [
111
In]-
In(oxinate)3 labelled eGFP-5T33 cells, 7 days after i.v. administration in 
haematopoietic tissues and kidneys in C57BL.KaLwRij mice 
4.4.2 In vivo study, Series 2 
 After finishing the procedures to label 3 separated tubes of eGFP-5T33 cells  
with [89Zr]-Zr(oxinate)4 (8.4 MBq, 15.9 MBq and 8.3 MBq), the labelled cell samples 
were pooled, the resulting 3.4 x 10
7
 labelled cells contained 14.7 MBq of [89Zr]-
Zr(oxinate)4 (cell labelling yield 45%), with cell viability 87%. 4.2 MBq of [89Zr]-
Zr(oxinate)4 labelled cells (9.7 x 10
6
 cells) was administered into a mouse for cell 















89Zr oxine labelled eGFP-5T33 cells 7 d




          30 min     2 hr       24 hr 
 
        48 hr  168 hr  
Figure 4.6: Whole body images of multiple myeloma mouse injected with [89Zr]-
Zr(oxinate)4 labelled eGFP-5T33 cells, at 30 min, 2 hr, 24 hr, 48 hr, 168 hr (7 days) 




                                      336 hr with CT                336 hr without CT 
 
Figure 4.7: Whole body images of multiple myeloma mouse injected with [89Zr]-
Zr(oxinate)4 labelled eGFP-5T33 cells, 336 hr (14 days, with CT and without CT) 
post inoculation.  
 Unfortunately, the mouse injected with the labelled cell lysate died ca. 5 min 





4.4.3 In vivo study, Series 3 
PET/CT imaging of dead/lysed [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells 
was performed and images were analysed at 30 min and 1 day after injection (Figure 
4.8).  
                
                    
             30 min       24 hr 
 
Figure 4.8: PET/CT whole body images of dead/lysed labelled [89Zr]-Zr(oxinate)4 
eGFP-5T33 cells in multiple myeloma mouse, at 30 min and 24 hr post injection. 
The results of ex vivo tissue counting of mice injected [89Zr]-Zr(oxinate)4 
labelled eGFP-5T33 at 9 hr, 24 hr and 48 hr post inoculation are shown in Tables 4.3-
4.4 and Figure 4.9. The liver was the organ with the highest levels of activity from a 
couple of hours post-injection for up to 2 days. Spleen also retained activity but less 
than in the liver, higher than in kidneys. However percentage of activity normalised to 
the mass of the spleen was higher than that in the liver. Greater activity was obtained 
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when mass of the bone (femur) was used to calculate % ID/g compared to the activity 
per tissue (femur) (% ID).  
 
% ID of 
89
Zr oxine labelled eGFP-5T33 cells in  




9 hr post  
Injection ( n=3) 
24 hr post 
injection ( n=4) 
48 hr post 
injection ( n=3) 
 
Heart 
0.18 ± 0.02 0.09 ± 0.02 0.08 ± 0.02 
                                             
         Lungs 
0.59 ± 0.11 0.45 ± 0.08 0.21 ± 0.04 
 
Liver 
69.26 ± 6.17 69.28 ± 11.93 57.58 ± 5.35 
 
Spleen 
5.82 ± 0.85 7.10 ± 0.96 4.74 ± 0.52 
            
Stomach 
0.14 ± 0.01 0.17 ± 0.06 0.12 ± 0.01 
 
Small intestine 
0.34 ± 0.05 0.31 ± 0.06 0.32 ± 0.04 
 
    Large intestine 
0.36 ± 0.04 0.30 ± 0.09 0.26 ± 0.10 
 
Kidneys 
1.80 ± 0.15 1.75 ± 0.18 1.42 ± 0.21 
                      
Muscle 
0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
 
Femur 
0.63 ± 0.08 0.82 ± 0.12 0.52 ± 0.04 
 
Salivary glands 
0.12 ± 0.004 0.11 ± 0.02 0.10 ± 0.03 
 
Blood 
0.39 ± 0.10 0.18 ± 0.10 0.10 ± 0.03 
 
Table 4.3: Whole body biodistribution of [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 
cells in multiple myeloma mice, presented in terms of percentage of the injected dose 






% ID/g of 
89
Zr oxine labelled eGFP-5T33 cells  




9 hr post  
Injection ( n=3) 
24 hr post 
injection ( n=4) 
48 hr post 
injection ( n=3) 
 
Heart 
0.85 ± 0.09 0.50 ± 0.13 0.32 ± 0.07 
                                             
         Lungs 
2.28 ± 0.41 1.35 ± 0.07 0.68 ± 0.06  
 
Liver 
44.63 ± 10.59 42.17 ± 9.13 30.90 ± 4.2 
 
Spleen 
74.95 ± 13.17 99.47 ± 10.95 54.90 ± 1.2 
            
Stomach 
0.29 ± 0.08 0.45 ± 0.17 0.28 ± 0.07 
 
Small intestine 
0.35 ± 0.01 0.34 ± 0.02 0.27 ± 0.07 
 
    Large intestine 
0.35 ± 0.04 0.27 ± 0.02 0.21 ± 0.04 
 
Kidneys 
3.94 ± 0.45 4.01 ± 0.44 3.00 ± 0.43 
                      
Muscle 
0.19 ± 0.03 0.21 ± 0.05 0.13 ± 0.03 
 
Femur 
7.12 ± 1.41 8.390± 0.47 5.30 ± 0.85 
 
Salivary glands 
0.54 ± 0.06 0.52 ± 0.14 0.44 ± 0.04 
 
Blood 
1.77 ± 0.1 1.03 ± 0.18 0.53 ± 1.68 
 
Liver : spleen 
0.60 ± 0.18 0.42 ± 0.10  0.56 ± 0.08 
 
Liver : femur 
6.28 ± 1.94 5.02 ± 1.12 5.83 ± 1.23 
 
Spleen : femur 
10.6 ± 2.78 11.9 ± 1.47 10.4 ± 1.68 
 
Liver : kidneys 
11.4 ± 3.0 10.6 ± 2.6  10.3 ± 2.0 
 
Spleen : kidneys 
19.2 ± 4.2 24.9 ± 3.9 18.3 ± 2.7 
 
Femur : kidneys 
1.8 ± 0.42 2.1 ± 0.26 1.8 ± 0.38 
 
Table 4.4: Whole body biodistribution of [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 
cells in multiple myeloma mice presented in terms of percentage of the injected dose 







Figure 4.9: Graphs of whole body biodistribution of [89Zr]-Zr(oxinate)4 labelled 
eGFP-5T33 cells in multiple myeloma mice, presented as (A) % ID and (B) % ID/g 
















9 hr after injection
24 hr after injection














9 hr after injection
24 hr after injection
48 hr after injection
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4.4.4 In vivo study, Series 4 
 FACS analysis of in vitro cultured J774 cells (negative for GFP) and eGFP-
5T33 cells are shown in Figure 4.10.  
 
                                                       
            (A)                          (B) 
Figure 4.10: Results of the FACS analysis comparing J774 cells (GFP negative, A) 
and eGFP-5T33 (GFP positive, B). 
 The liver, spleen and bone marrow were harvested from [89Zr]-Zr(oxinate)4 
labelled cells injected mice at day 2 and day 7 post inoculation. The organs were 
homogenised and analysed by FACS as shown in Figure 4.11 and 4.12 for the organs 















                    
  (A)             (B)             (C) 
Figure 4.11: Representative FACS results of organ homogenates of MM model 
injected [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells 2 days after injection, in A= 
liver, B=spleen and C=bone marrow. (n=3 for each organ) 
 
               
                (A)                (B)             (C) 
Figure 4.12: Representative FACS results of organ homogenates of MM model 
injected [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells 7 days after injection, in A= 














After FACS sorting of organ homogenates based on eGFP expression from 
injected [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 mouse culled after inoculation for 2 
days and  7 days, most of the activity was present in the GFP+ cells compared to GFP- 
cell in the same organ homogenates (Figure 4.13). The GFP+ cell populations 
contained significantly higher activity per cell by a factor of > 23 and > 12 at day 2 and 
day 7, respectively, than GFP- samples.  
              
Figure 4.13: Activities in GFP positive and GFP negative cell populations sorted 
from the livers, spleens and femoral marrow (BM) organ homogenates harvested 
from mice 2 and 7 days after intravenous injection with [89Zr]-Zr(oxinate)4 labelled 





























Day 2 Day 7
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4.4.5 In vivo study, Series 5 
 Biodistribution of [89Zr]-Zr(oxinate)4 in MM mouse was investigated by PET 
imaging for 30 min after intravenous injection of 4 MBq [89Zr]-Zr(oxinate)4 and again 
at 24 hr as shown in Figure 4.14. For the early time point, the activities were observed 
in the heart, lungs, liver, spleen and faint activity in the kidneys. After 24 hr, the 
activity remained in those organs while increased activity in the spleen was observed. 
                                                                                
               
    
  30 min                                             1 day 
Figure 4.14: Distribution of [89Zr]-Zr(oxinate)4 in a C57BL/KaLwRij mouse, 




4.4.6 In vivo study, Series 6 




in the form of 
89
Zr oxalate in C57BL/6J 
mouse was investigated by intravenous injection of 5 MBq of neutralised 
89
Zr via tail 
vein then scanning for 30 min, with further imaging at 24 hr post administration. The 
images are shown in Figure 4.15.   
 
                                   
        4 hr                  24 hr 






Zr oxalate) in a C57BL/6J 
mouse, the images were obtained 4 hr and 24 hr after injection. 
The results of biodistribution of neutralised 
89
Zr, determined by ex vivo organ 
counting,
 
are summarised and represented as a percentage of injected dose per organs 





% ID of neutralised 
89
Zr 




2 days post 
Injection (n=3) 




0.34 ± 0.03 0.19 ± 0.01 
 
Lungs 
1.29 ± 0.09 0.32 ± 0.04 
 
Liver 
5.18 ± 0.97 6.18 ± 0.10 
 
Spleen 
0.28 ± 0.04 0.32 ± 0.05 
 
Stomach 
0.32 ± 0.05 0.19 ± 0.02 
 
Small intestine 
1.26 ± 0.09 0.41 ± 0.05 
 
Large intestine 
0.80 ± 0.15 0.49 ± 0.08 
 
Kidneys 
1.20 ± 0.07 0.83 ± 0.04 
 
Muscle 
0.09 ± 0.02 0.09 ± 0.01 
 
Femur 
2.32 ± 0.20 1.97 ± 0.21 
 
Salivary glands 
0.45 ± 0.07 0.37 ± 0.04 
 
Blood 
0.47 ± 0.04 0.04 ± 0.01 
 




in C57BL/6J mice, 









% ID/g of neutralised 
89
Zr 




2 days post  
Injection (n=3) 




1.34 ± 0.04 0.73 ± 0.03 
                                             
           Lungs 
2.54 ± 0.40 0.70 ± 0.03 
 
Liver 
3.16 ± 0.28 3.15 ± 0.22 
 
Spleen 
3.01 ± 0.25 3.05 ± 0.34 
            
Stomach 
0.51 ± 0.05 0.34 ± 0.10 
 
Small intestine 
0.91 ± 0.08 0.28 ± 0.03 
 
    Large intestine 
0.68 ± 0.10 0.31 ± 0.04 
 
Kidneys 
2.37 ± 0.20 1.74 ± 0.20 
                      
Muscle 
0.52 ± 0.05 0.66 ± 0.01 
 
Femur 
22.82 ± 2.70 23.22 ± 0.74 
 
Salivary glands 
1.86 ± 0.20 1.81 ± 0.14 
 
Blood 
2.19 ± 0.12 0.22 ± 0.01 
 




in C57BL/6J mice 
presented in terms of % ID/g, (percentage of the injected dose normalized with 





To obtain labelled eGFP-5T33 cells for in vivo studies, cells were labelled with 
each extraction of [89Zr]-Zr(oxinate)4. In order to investigate either in vivo imaging or 
ex vivo tissue counting, relatively high activity of radiolabelled cells was required 
compared to in vitro studies. Altogether, 2-3 extractions of [89Zr]-Zr(oxinate)4 were 
required to separately label separate aliquots of cells and then radiolabelled cells were 
washed and pooled together to achieve the adequate activity of radiolabelled cells for 
in vivo studies or ex vivo tissue counting experiments. 
Cell labelling yields for in vivo studies provide additional data supporting the 
results in Chapter 3. eGFP-5T33 cells were labelled with [89Zr]-Zr(oxinate)4 with a 
labelling efficiency of 43.16% ± 6.39 (between 35% and 52.30%) whereas the 
labelling efficiency with [
111
In]-In(oxinate)3 was 82.86% and 94%, with more than 10
7
 
cells being labelled for both of tracers. Comparing to the labelling of [
111
In]-
In(oxinate)3, cell labelling yields of [
89Zr]-Zr(oxinate)4 were lower than with [
111
In]-
In(oxinate)3 but still sufficiently promising as a basis for further optimisation. 
For the in vivo tracking of labelled eGFP-5T33 cells with either [89Zr]-
Zr(oxinate)4 or [
111
In]-In(oxinate)3, the labelled cells were in the blood circulation and 
transiently accumulated in the lungs and heart before rapidly migrating to the liver, 
spleen and skeleton. Radioactivity largely remained in those organs for at least 7 days. 
These data confirm that 5T33 cells home to haematopoietic organs (liver and spleen) 
and skeleton with high affinity in the multiple myeloma mouse model. Comparing our 
results to another multiple myeloma cell line, 5T2, the biodistribution of which was 
investigated by labelling with 
51
Cr, similar biodistribution was observed to that 
reported by Vanderkerken and colleagues (153).  
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Apart from these main target organs, we also observed faint activity in the 
kidneys at the early time points in mice injected with [89Zr]-Zr(oxinate)4 labelled cells 
and to a much higher level with [
111
In]-In(oxinate)3 labelled cells. According to 




89Zr]-Zr(oxinate)4 from living or dead labelled cells in vivo. This was 
consistent with the results of the control experiments in which the lysate of 
radiolabelled eGFP-5T33 cells was investigated in order to determine the fate of 
released activity in the dead labelled cells in vivo. The results may thus be interpreted 
as indicating that the retention of 
89




However in the first series of imaging, the results of tissue distribution of 
[89Zr]-Zr(oxinate)4 and [
111
In]-In(oxinate)3 labelled cell lysates 24 hr after injection, the 
activity was mainly accumulated in the liver, spleen and skeleton, a pattern similar to 
the imaging of live radiolabelled cells. Meanwhile activity in the kidneys was faintly 
detected. According to a previous study that had been carried out in our group by Dr. 
Levente Meszaros, lysed [
111
In]-In(oxinate)3 labelled eGFP-5T33 cells clear rapidly via 
kidneys 24 hr after inoculation, this is likely to be due to “In-111-labelled” proteins 
released by cells. Thus results obtained in this experiment indicate that live or viable 
labelled cells were still present in the suspension after repeated flash-freezing and 
thawing. Also the images of lysed [89Zr]-Zr(oxinate)4 labelled cells showed similar 
organ accumulation to that of lysed [
111
In]-In(oxinate)3 labelled cells. This indicated 
that some of the labelled cells remained viable according to the significant levels of 
radioactivity present in the liver, spleen and bone marrow, but renal uptake (to a much 
greater extent than with live cells) was also observed. So the results were very similar 




cell lysate.  
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Therefore we repeated the control experiment in the second series study with 
an improved procedure to kill the labelled cells by repeatedly freezing the cells in 
liquid N2 and thawing at 95
o
C. In this case the injected mouse was dead several 
minutes after administration of lysate [89Zr]-Zr(oxinate)4 labelled cells. This may have 
been caused by aggregation of the cell lysates resulting in suspected pulmonary 
embolus. So we improved the procedure for preparation of the cells lysates using 
subsequent passage through different gauges of needle to disintegrate aggregation of 
the cell lysates before administration to the mouse in the third series of imaging. This 
improved procedure was able to overcome the problem. 
Data obtained in the third series of imaging of labelled cell lysates showed 
accumulation in the liver, spleen and skeleton as well as in the kidneys both for [89Zr]-
Zr(oxinate)4 and [
111
In]-In(oxinate)3. The activities in the bones might indicate that a 
small amount of live radiolabelled cells presented in the suspension injected to the 
mouse, or may be due to other reasons.  There was more uptake in the kidneys at 24 hr 
post inoculation compared to the early time point at 30 min after administration. These 
findings suggest that fate of radioactivity released from the labelled cells can be 




In bound to large proteins from the cytoplasmic components in the labelled 
cells could be accumulated in the liver whereas the fractions bound to smaller proteins 
or peptides may be trapped in the kidneys. Radiolabelled molecules metabolised in the 
liver may subsequently be released and then trapped in the kidneys.  
Table 4.1 shows that activity from liver, spleen and bone marrow of mice 
inoculated [
111
In]-In(oxinate)3 labelled cells was significantly less than that of eGFP-
5T33 cells labelled with [89Zr]-Zr(oxinate)4 at 7 days after administration (Figure 4.5). 










In]-In(oxinate)3, higher activities were 
accumulated in the kidneys 24 hr after inoculation, is consistent with the hypothesis 
that any Zr-89 released from labelled cells in vivo is slower for Zr-89 than for In-111. 
This is an important observation as it indicates that Zr-89 shows great promise for 
tracking cells in vivo over long periods. 
Results of FACS analysis of in vitro culture of eGFP-5T33 cells confirmed that 
the cells strongly express GFP (more than 97% of cells) as expected, compared to 
negative control J774 cells, which do not express GFP. This result suggests that eGFP-
5T33 cells could be used for sorting cells isolated from mice based on GFP expression 
followed tracking labelled cells in vivo. The results of ex vivo FACS sorting of GFP 
positive and GFP negative populations from organ homogenates (liver, spleen, bone 
marrow) prove that GFP positive cells contained significantly higher activity than GFP 
negative cells. In other words [89Zr]-Zr(oxinate)4 labelled cells retained the radiolabel 
in vivo at least for a week, and do not transfer a significant  fraction of their 
radioactivity to other cells. In addition, these results would prove that eGFP-5T33 cells 
labelled with [89Zr]-Zr(oxinate)4 were alive in vivo for up to 7 days because only live 
cells are able to express GFP.  
The biodistribution results of [89Zr]-Zr(oxinate)4 in the multiple myeloma 
mouse show accumulation of activity in the organs with a high blood supply including 
heart, lungs, liver and spleen at 30 min after injection. On the following day, activity 
still remained in those organs but the activity in the lungs was decreased whereas 
increased activity was observed in the spleen at 24 hr after administration. This 
biodistribution pattern of [89Zr]-Zr(oxinate)4 is similar to that of [
111
In]-In(oxinate)3 in 
glioma bearing nude rat which was reported by Varma et al. (155). The biodistribution 
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of [89Zr]-Zr(oxinate)4 within the high blood flow organs might be due to potential to 
label red blood cells in the similar manner to gallium-68 oxine labelling red blood cells 
(97) or to uptake in cells of the well-perfused organs. 
According to the information obtained from the biodistribution of [89Zr]-
Zr(oxinate)4 labelled eGFP-5T33 cells and [89Zr]-Zr(oxinate)4 in multiple myeloma 
mouse, liver, spleen and bone marrow were the main accumulation activity organs for 
both of radiotracers. However the presented activities in those organs of mouse 
injected [89Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells were not related to [89Zr]-
Zr(oxinate)4. This conclusion was confirmed by the results of the ex vivo FACS sorting 
cells which the detected radioactivity was associated with the GFP positive cells rather 
than free radiotracer unbound to the cells or bound to other cells.  
Comparing our in vivo imaging of neutralised 
89
Zr (which is in the form of 89Zr 
oxalate) in C57BL/6J mouse with those in NIH Swiss mouse reported by D.S. Abou et 
al., the biodistribution of the tracer was similar (156). At the early time point, for 30 
min post injection, radioactivity in the blood pool was observed with significant 
activity also localised in the bones and joints. After 24 hr, activity was completely 
cleared from blood pool, only accumulation activity in the skeleton and joints 
remained. This result was concordant with the results of the ex vivo tissue counting 
which showed that activity in the circulation and in the vascular organs was decreased 
between 2 days to 7 days post injection in contrast with the persistent activity in the 
bones up to 7 days. Altogether these results of 89Zr oxalate biodistribution in C57BL/6J 






 eGFP-5T33 cells were successfully labelled with [89Zr]-Zr(oxinate)4 and used 
for in vivo tracking of labelled cells in a multiple myeloma mouse model, 
C57BL/KaLwRij, for up to two weeks. Comparing [89Zr]-Zr(oxinate)4 and [
111
In]-
In(oxinate)3 labelled eGFP-5T33 cells showed no qualitative difference in the homing 
organs of the radiolabelled cells. Although the tissue biodistribution of [89Zr]-
Zr(oxinate)4 labelled cells was similar to that of [
111
In]-In(oxinate)3, a standard 
radiotracer for labelling cells, in vivo stability of [89Zr]-Zr(oxinate)4 labelled cells was 
greater than those of [
111
In]-In(oxinate)3 after longer periods of tracking the cells. 
[89Zr]-Zr(oxinate)4 labelled eGFP-5T33 cells were also proved to retain the radiolabel 
and remain viable in in vivo for at least a week according to the results of ex vivo 
FACS sorting based on GFP expression. Therefore, the lipophilic complex of [89Zr]-
Zr(oxinate)4 is a very promising long lived PET radiotracer to label and track cells 




Chapter 5: Summary and future work 
The studies in this thesis reported on the production and characterisation of 
complexes of 
64
Cu, a relatively long lived PET isotope, with dithiocarbamates (DTC) 
and bis(thiosemicarbazones) (BTSCs). The synthesis protocol was simple, fast and 
efficient to produce radiocopper complexes with either DTC or BTSC ligand. Copper-
64 complexes of DTCs and BTSCs were shown the acceptable quality for further in 
vitro studies.  




Cu (DEDTC)2 and 
64
Cu GTSM showed rapid and high extraction into various cell types. Although both 
types of tracers were able to efficiently influx into the cells, the retention of the activity 
in the labelled cells decreased rapidly after labelling. Less than 30 % of 
64
Cu activities 
were retained in the cells 24 hr post labelling for all the lipophilic complexes of 
64
Cu. 
Based on the results, therefore, those lipophilic complexes of copper are not suitable 
for long period tracking of the labelled cells especially in the application of cell based 
therapy and alternative PET labels were sought. 
The physical half life of 
89
Zr (3.2 days) offers opportunity for sequential 
imaging studies longer period of time and its decay properties are good for PET 
imaging.  Therefore the later part of this thesis describes synthesis and characterisation 
of a new 
89
Zr lipophilic complex, [89Zr]-Zr(oxinate)4, to label cells. Although the 
quality of [89Zr]-Zr(oxinate)4 was suitable for the following experiments either in vitro 
or in vivo, the quantity of the radiotracer was lower than expected when high initial 
activity was used (in order to use in in vivo studies). The issue of suboptimal 
production for required high activity of [89Zr]-Zr(oxinate)4 will need to be addressed 
for further improvement.    
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In vitro studies of intracellular uptake and efflux of [89Zr]-Zr(oxinate)4 by 
several cell types (macrophages (J774), breast cancer cells (MDA-MB-231) and mouse 
multiple myeloma cells (eGFP-5T33)) were performed. [89Zr]-Zr(oxinate)4 was 
moderately taken up by the cell lines including human white blood cells. However, 
high retention activity in the labelled cells 24 hr post labelling compared to that of 
[
111
In]-In(oxinate)3 (which is and approved radiotracer for labelling cells in clinical 
practice) was exhibited. This finding suggested that [89Zr]-Zr(oxinate)4 could be 
beneficially used to label cells for tracking over longer time periods because greater 
stability of the radiotracer in the labelled cells can be achieved. 
This project also achieved the successful labelling of eGFP-5T33 cells with 
[89Zr]-Zr(oxinate)4 for both in vitro experiments and in vivo tracking of labelled cells in 
a multiple myeloma mouse model, C57BL/KaLwRij. In vivo cell tracking and ex vivo 
biodistribution of [89Zr]-Zr(oxinate)4 labelled cells were compared to those of [
111
In]-
In(oxinate)3 labelled eGFP-5T33 cells showed the similar main organs of homing: 
liver, the spleen and the skeleton. The experiment of imaging lysates of cells labelled 
with [89Zr]-Zr(oxinate)4 and [
111
In]-In(oxinate)3 suggested that the released activity 
from the labelled cells in vivo could subsequently taken up or excreted via the kidneys. 
At the longer period of tracking labelled cells, in vivo stability of [89Zr]-Zr(oxinate)4 
labelled cells was superior to that of cells labelled with [
111
In]-In(oxinate)3 as less 
accumulation of released activity in the kidneys was observed. [89Zr]-Zr(oxinate)4 
labelled eGFP-5T33 cells were also confirmed to retain the radiolabel, and to remain 
viable in vivo for at least a week, according to the results of FACS sorting of organ 
homogenates based on GFP expression. In vivo imaging of [89Zr]-Zr(oxinate)4 labelled 
cells was successful in tracking the labelled for up to two weeks. 
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In order to improve synthesising yield and cell labelling yield, alternative 
ligands such as tropolone or MPO (2-mercaptopyridine-N-oxide) should undergo 
investigations since those ligands have shown the possibility to label cells with a range 
of radionuclides and radiocomplexes.    
Based on the half life of 
89
Zr, this novel lipophilic PET tracer should be useful 
for the application of tracking cells especially for stem cell or immune cell therapy 
where longer tracking of labelled cells is required. This would offer superior 
observation of the retention of labelled stem cells in homing tissues or organs and also 
lead to better understanding the mechanism of labelled cells in cell based therapy. 
Therefore further investigation of labelling [89Zr]-Zr(oxinate)4 with those cells will be 
considered.  
Although this work described the promise of [89Zr]-Zr(oxinate)4 as a PET tracer 
for labelling cells and prolong tracking radiolabelled cell in vivo, the aspect of 
radiation biology and toxicity of this tracer to the labelled cells has not been yet 
investigated. Comparison of toxicity to radiolabelled cells and alteration of labelled 
cell function between 89Zr and 111In will be need to be done. There is not only radiation 
affect to labelled cells to consider but also the radiation dosimetry and radiation 
protection for related working staff, other people and environment should be 
determined. 
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